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One Sentence Summary 
Class I cytokine receptors are activated by ligand-induced dimerization that triggers Janus kinase 
interaction and activation via their regulatory pseudokinase domains. 
Abstract 
Homodimeric class I cytokine receptors are assumed to exist as preformed dimers that are activated by 5 
ligand-induced conformational changes. Here, we have quantified dimerization of three prototypic class I 
cytokine receptors in the plasma membrane of living cells by single-molecule fluorescence microscopy. 
Spatial and spatiotemporal correlation of individual receptor subunits showed ligand-induced 
dimerization and revealed that the associated Janus kinase-2 (JAK2) dimerizes through its pseudokinase 
domain. Oncogenic receptor and hyperactive JAK2 mutants promoted ligand-independent dimerization, 10 
highlighting the formation of receptor dimers as the switch responsible for signal activation. Atomistic 
modeling and molecular dynamics (MD) simulations based on a detailed energetic analysis of the 
interactions involved in dimerization yielded a mechanistic blueprint for homodimeric class I cytokine 
receptor activation and its dysregulation by individual mutations. 
  15 
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Main text 
Cytokines bind their cognate receptors to regulate hematopoiesis and immunological homeostasis. 
Consequently, imbalances in levels of circulating cytokines, or mutations that alter cytokine receptor 
function, can lead to severe pathological effects, ranging from aberrant immune responses to 
hematological malignancies. Therefore, a complete understanding of the dynamics and mechanisms 5 
underpinning cytokine receptor activation is critical. 
The class I cytokine receptor family includes receptors for interleukins, colony-stimulating factors and 
hormones. These receptors lack intrinsic kinase activity, relying instead on associated Janus kinase (JAK) 
proteins to initiate signal transduction. The precise activation mechanism of class I cytokine receptors, 
however, remains unclear (1). Originally, ligand-induced receptor dimerization was assumed to trigger 10 
signal activation (2). However, this model has been replaced by more complex concepts that propose 
ligand-induced conformational changes of pre-dimerized receptor subunits (Fig. 1A) (1, 3, 4). Supported 
by extensive structural and biochemical studies, homodimeric class I cytokine receptors such as the 
erythropoietin (Epo) and growth hormone (GH) receptors have become a paradigm for pre-assembled 
receptor dimers (1)(5-7). Moreover, pre-dimerization has also been reported for numerous heterodimeric 15 
class I and class II cytokine receptors (8-12), suggesting that receptor pre-dimerization may be a generic 
feature of this receptor family (1, 4). However, the molecular mechanism responsible for triggering JAK 
activation by preformed receptor dimers has remained rather speculative. Current models cannot 
convincingly explain receptor dysregulation by constitutively activating, oncogenic JAK mutations. 
Notably, hyperactivity of JAK2 caused by somatic mutations, such as JAK2 V617F, is the most common 20 
cause of the Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPNs) (13, 14). 
Gaining a mechanistic understanding of pathway activation could inspire more specific strategies to target 
aberrant signaling underlying such MPNs.  
Directly observing the spatiotemporal organization of cytokine receptors in the plasma membrane of 
living cells under physiological conditions has been hindered by their very low cell-surface expression 25 
levels, which are below the detection limit of conventional fluorescence microscopy (15, 16). We devised 
a method for quantifying the monomer-dimer equilibrium of homodimeric class I cytokine receptors at 
physiological densities in the plasma membrane by dual-color single-molecule fluorescence imaging in 
combination with posttranslational cell-surface labeling. We find that thrombopoietin receptor (TpoR), 
Epo receptor (EpoR) and GH receptor (GHR) are monomeric and randomly distributed in the plasma 30 
membrane in the resting state, yet efficiently dimerize upon ligand binding. By quantifying the monomer-
dimer equilibrium for various receptor and JAK variants, we obtain a comprehensive energetic landscape 
of ligand- and oncogene-induced receptor dimerization revealing finely tuned, additive interactions 
involving JAK and receptor domains. Based on these quantitative insights in conjunction with atomistic 
MD simulations, we suggest a mechanism of homodimeric class I cytokine receptor activation by ligand-35 
induced dimerization, which can explain their dysregulation by individual mutations. 
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Results 
Random distribution and diffusion of TpoR in the plasma membrane 
For time-lapse dual-color single-molecule imaging at the plasma membrane of live HeLa cells by total 
internal reflection fluorescence microscopy (TIRFM), receptor subunits were stochastically labeled with 
photostable fluorescent dyes by using equal concentrations of anti-GFP nanobodies conjugated to either 5 
Rho11 (Rho11NB) or DY647 (DY647NB) (Fig. 1A). To this end, EpoR, TpoR and GHR were N-terminally 
fused to monomeric enhanced green fluorescent protein (mEGFP), which was rendered non-fluorescent 
by the mutation Y66F (mXFP). Since the endogenous JAK2 levels in HeLa cells are negligibly low, 
JAK2 fused to mEGFP (JAK2-mEGFP) was co-expressed with the receptor subunit to verify functional 
integrity at the single cell level. Efficient association of JAK2-mEGFP with the receptor (fig. S1), as well 10 
as uncompromised activity of mXFP-tagged receptor and JAK2-mEGFP (fig. S2, fig. S3A), were 
confirmed. Representative results of dual-color single-molecule imaging experiments obtained for mXFP-
TpoR expressed in HeLa cells are summarized in Fig. 1B-F. After labeling with Rho11NB and DY647NB, 
individual TpoR randomly diffusing in the plasma membrane could be discerned (Fig. 1B and Movie S1). 
The presence of individual receptor subunits was confirmed by single-step photobleaching at elevated 15 
laser power (Movie S2 and fig. S4A). Long-timescale single-molecule localization microscopy of TpoR 
confirmed largely homogeneous spatiotemporal distribution across the plasma membrane (fig. S4B). 
Despite co-expression of JAK2, a low cell surface receptor density was obtained with typically 0.4-0.5 
molecules/µm² in each spectral channel and a Rho11/Dy647 ratio close to unity (Fig. 1B). Taking into 
account an effective labeling degree of ~70% achieved by both Rho11NB and DY647NB (fig. S4C), the total 20 
cell-surface concentration of receptor subunits was ~1-1.5 molecules/µm². Very similar cell surface 
densities of endogenous TpoR were found in UT-7/Tpo cells, a megakaryocytic cell line commonly used 
for functional studies on TpoR (17), as quantified by flow cytometry experiments with fluorescence-
labeled Tpo (fig. S4D). These observations confirm the physiological relevance of low cell surface 
expression in our model system and suggest that TpoR cell surface densities are under tight control. 25 
Ligand-induced TpoR dimerization revealed by single-molecule co-tracking 
Receptor dimerization was quantified by co-localization and co-tracking of individual receptor subunits 
detected in both spectral channels taking into account that, statistically, only half of the dimerized 
receptors are labeled with two different colors (see methods section). This method was calibrated based 
on negative and positive control experiments with a model transmembrane protein that was dimerized via 30 
a monoclonal antibody (Movie S3, fig. S5A). For TpoR coexpressed with JAK2, very few (on average 
less than one per cell) co-trajectories of Rho11NB and DY647NB-labeled receptors could be detected in the 
absence of ligand (Movie S4 and Fig.1C). By contrast, strong TpoR dimerization was observed upon 
addition of Tpo, yielding a large number of single-molecule co-trajectories (Movie S4 and Fig. 1C). The 
stoichiometry of TpoR homodimers was confirmed by single- and dual-color photobleaching experiments 35 
(Fig. 1D, E and fig. S5B). The significant increase in Rho11 fluorescence upon photobleaching of DY647 
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indicated FRET within co-locomoting TpoR dimers, confirming molecular proximity within ligand-
induced TpoR dimers (Fig. 1E and fig. S5C). TpoR dimerization levels increased up to a concentration of 
10 nM Tpo, and then decreased at elevated concentrations, yielding a bell-shaped dose-dimerization curve 
that essentially matched the bell-shaped dose-response curve of STAT5 phosphorylation (fig. S3A, B). 
This concentration-dependent self-inhibition can be explained by a gradual shift from a 1:2 to a 1:1 5 
Tpo:TpoR stoichiometry. Ligand-induced receptor dimerization was accompanied by a small, yet 
significant decrease of ~25% in the overall diffusion constant (fig. S5D and Table S1) that can be 
ascribed to the increased friction within the membrane for receptor dimers compared to monomers (18, 
19). Furthermore, the fraction of immobile receptors increased after addition of ligand (Table S1), which 
is in line with receptor endocytosis upon activation (20, 21). Very similar diffusion properties in the 10 
absence and presence of Tpo were obtained for TpoR labeled via the 21 amino acid E3-tag (22) (fig. S5D 
and Table S1), confirming minimal bias of receptor diffusion and interaction by the mXFP tag. 
Significantly lower levels of ligand-induced dimerization were observed in the absence of JAK2 (Fig. 
2A). The diffusion constants of TpoR monomers and dimers were ~15% lower when JAK2 was co-
expressed (fig. S5E and Table S1). 15 
Dissociation of ligand-induced TpoR dimers was observed very rarely within the experimental time 
frame. A reliable determination of complex lifetimes was therefore not possible due to a lack of co-
tracking fidelity as well as photobleaching. These observations suggest that the stability of ligand-induced 
TpoR dimers is high compared to the imaging time resolution. To exclude that TpoR pre-dimerization 
was missed by co-tracking analysis due to very short dimer lifetimes in the absence of ligand, we 20 
quantified the spatial organization of receptor subunits in the plasma membrane by particle image cross-
correlation spectroscopy (PICCS)(23) of individual TpoR detected in both channels. Spatial cross-
correlation above the background was only observed after adding the ligand (Fig. 1F, fig. S6C and Table 
S2), yielding similar dimerization levels to those determined by co-locomotion analysis. Quantification of 
the relative number of co-trajectories yielded ligand-induced dimerization levels of 75% compared to a 25 
positive control based on a model transmembrane protein that was dimerized by a high-affinity 
monoclonal antibody (Fig. 2A, Movie S3). Antibody-induced dimerization of the model transmembrane 
protein reduced its diffusion constant in a similar way to that observed for ligand stimulation of TpoR 
(Table S1). 
Comparable spatiotemporal dynamics of TpoR, EpoR and GHR dimerization 30 
For EpoR and GHR, very similar properties with respect to diffusion and interaction in the plasma 
membrane were observed: the receptor cell surface expression was low as previously found for EpoR in 
erythroid cell types (15) and in binding experiments with labeled GH bound to endogenous GHR in GH-
responsive (24) HuH7 cells (fig. S7, fig. S8). Uncorrelated receptor diffusion was observed in the absence 
of ligand, and efficient dimerization occurred in the presence of ligand with a bell-shaped concentration 35 
dependence (Fig. 2A, Movie S5, S6 and fig. S3B, S7A, B, S8A, B). Similar levels of ligand-induced 
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dimerization (50% and 60% for EpoR and GHR, respectively) were observed, which depended on the 
presence of JAK2, as well as similar changes in the diffusion properties (Fig. 2A, fig. S7C, S8C and 
Table S1). However, assays with GHR using cells cultured in the presence of fetal calf serum were 
strongly biased by traces of bovine GH (fig. S8D). For this reason, dimerization was quantified after 
serum starving and scavenging of residual bovine GH by adding purified soluble GHR ectodomain. 5 
Under these conditions, ligand-induced dimerization was unambiguously confirmed for GHR. By 
contrast, antagonistic Epo (S126E) and GH (G146R) mutants (25, 26) did not dimerize their receptors in 
the plasma membrane (fig. S7D, S8E).  
JAK2 PK domains contribute to receptor dimerization 
The increased levels of ligand-induced dimerization that were obtained for all three receptors in the 10 
presence of JAK2 (Fig. 2A) suggest that the associated JAKs energetically contribute to receptor 
dimerization. To exclude that dimerization was enhanced by downstream signal activation, we compared 
TpoR dimerization in the absence and presence of the JAK2 inhibitor Ruxolitinib, which remained 
unchanged (Fig. 2B). These observations suggested stabilizing interactions between the associated JAKs, 
which have been implicated in regulating the activation of receptor tyrosine kinases (27). JAKs are 15 
comprised of four domains: the intimately connected N-terminal FERM and SH2-like domains (FS) bind 
the receptor through its membrane proximal box 1 and box 2 motifs (Fig. 2C, D), whilst the C-terminal 
tyrosine kinase (TK) is regulated by the adjacent pseudokinase (PK) domain, which lacks tyrosine kinase 
activity. To identify the role played by the TK and PK domains in contributing to the additional binding 
energy, we quantified TpoR dimerization in the presence of JAK2 variants in which the TK domain 20 
(JAK2 TK) or both TK and PK domains were truncated (JAK2 PK-TK) (Fig. 2C). These experiments 
established that stabilization of ligand-induced dimers was maintained in the absence of the TK domain, 
but was abrogated for JAK2 PK-TK (Fig. 2E). 
The oncogenic JAK2 V617F mutation induces ligand-independent receptor dimerization 
These data suggest that intermolecular JAK2 interactions involving the PK domains may be important for 25 
JAK activation. The JAK2 PK domain is the primary site of somatic mutations in Ph- MPNs (14, 28). For 
example, JAK2 V617F is hyperactive (fig. S2C), and the consequent factor-independent proliferation 
relies on the co-expression of a homodimeric class I cytokine receptor, usually either EpoR or TpoR, at 
the cell surface (29, 30). However, the mechanisms underlying JAK2 V617F activation remain elusive. 
Strikingly, co-expression of JAK2 V617F yielded substantial ligand-independent dimerization of TpoR, 30 
EpoR and GHR (Movie S4-S6, Fig. 3A). Compared with ligand-induced dimerization, ligand-
independent dimerization in the presence of JAK2 V617F reached ~50% of the maximum level for TpoR, 
~25% for EpoR and ~10% for GHR, respectively. Single-molecule photobleaching confirmed that JAK2 
V617F induced formation of TpoR dimers, and single-molecule FRET (smFRET) confirmed molecular 
proximity of both subunits (fig. S9A). Ligand-independent JAK2 V617F-induced receptor dimers showed 35 
very similar diffusion properties to the corresponding ligand-induced receptor dimers in the presence of 
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JAK2 wt (fig. S5E, S7E, S8G and Table S1). Somewhat higher FRET efficiencies were observed for 
ligand-independent dimerization of TpoR in the presence of V617F compared to TpoR dimers formed in 
the presence of Tpo (fig. S9A), suggesting differences in the structural organization of the receptor 
ectodomains in these dimers. Ligand-independent dimerization of TpoR in the presence of JAK2 V617F 
does not rely on JAK2 TK activity as confirmed by treatment with ruxolitinib (Fig. 2B). Moreover, no 5 
dimerization of TpoR by JAK2 V617F was found for a box 1/box 2 mutant (TpoR Box 1+2) that is 
defective in JAK recruitment to the receptor (Fig. 2B).  
Additional molecular determinants contribute to JAK2 V617F-mediated dimerization 
These results support our hypothesis that JAK2 V617F short-circuits ligand-induced receptor 
dimerization and highlight the critical role of the PK domain. We therefore explored in more detail the 10 
molecular determinants of JAK2 V617F-induced dimerization of TpoR. Combination of V617F with the 
mutation F595A, which effectively abolishes constitutive activation by V617F (31), largely neutralized 
ligand-independent dimerization of TpoR by JAK2 V617F (Fig. 3B). In the absence of the tyrosine kinase 
domain (TK), JAK2 V617F dimerized TpoR in a ligand-independent manner, and remained sensitive to 
the combination with F595A (Fig. 3B). Strikingly, dimerization and activation of TpoR by JAK2 V617F 15 
occurred independently of the receptor ectodomain (Fig. 3B, Movie S7 and fig. S9B, C). Taken together, 
these results suggest that the V617F mutation enhances interactions between the PK domains. Further 
enhanced dimerization levels of TpoR were observed in the presence of Tpo and JAK2 V617F (Fig. 2E). 
The substantial differences observed between JAK2 V617F-induced dimerization of EpoR, TpoR and 
GHR, however, suggested that the receptor itself also contributes to dimerization. We therefore explored 20 
whether JAK2 V617F was capable of driving homodimerization of the interferon- receptor subunit 
IFNGR2. Significant, though much lower dimerization compared to EpoR, TpoR and GHR was observed 
for IFNGR2 (Fig. 3C), confirming the critical role of the receptor in JAK2 V617F-mediated dimerization. 
JAK2 V617F was even capable of driving substantial heterodimerization between mXFP-TpoR and 
SNAPf-EpoR (Fig. 3C, Movie S8), corroborating that ligand-independent dimerization was largely driven 25 
by JAK2 V617F. 
Membrane-proximal amphipathic segment is involved in receptor dimerization 
To shed light on potential interactions directly mediated by the receptor, we focused on the 
juxtamembrane (JM) amphipathic motif of TpoR (Fig. 2D), which is critical in regulating TpoR activation 
(32). Most prominently, the mutation W515L is an oncogenic mutation that constitutively activates TpoR 30 
signaling (33). Structural studies on the transmembrane (TM) and JM domains of TpoR by solid state 
NMR have suggested that W515L enhances interaction of the TM domains (34). Similar weak 
interactions between the TM domains have been reported for EpoR (35) and GHR (6, 7). Strikingly, we 
observed substantial dimerization of TpoR W515L in the absence of ligand (Fig. 3D). While ligand-
independent dimerization of TpoR W515L in the absence of JAK2 was weak and transient, stronger and 35 
more stable dimerization was observed upon co-expression of JAK2 (Fig. 3D and Movie S9), confirming 
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cooperative interactions mediated by TpoR TM-JM and JAK2 PK domains. Likewise, a significant (but 
lesser) increase in ligand-independent dimerization was observed for TpoR W515L when co-expressing 
TYK2 instead of JAK2. TYK2 complements the activity of TpoR in the absence of JAK2, though with 
lower potency (36). While deletion of the TK domains further increased ligand-independent TpoR 
W515L dimerization (Fig. 3D), truncation of the PK domain decreased dimerization to the level in the 5 
absence of JAK2/TYK2 (Fig. 3D), confirming productive PK-PK interactions in W515L-induced dimers. 
Ligand-independent dimerization was enhanced upon co-expression of TpoR W515L with JAK2 V617F 
(Fig. 3D), highlighting the additive nature of these interactions, in line with their additivity in ligand-
independent signaling activities (37). 
Additive interactions control the assembly of the signaling complex 10 
To quantify the different energetic contributions involved in the assembly of the TpoR signaling complex, 
we converted dimerization levels into two-dimensional equilibrium dissociation constants (ܭ஽ଶ஽), 
according to the law of mass action for a monomer-dimer equilibrium (Fig. 4A and Table S3). These were 
used to estimate the energetic contributions, G, of the different interaction sites within the receptor as 
schematically outlined in Fig. 4B. The G values were determined assuming that ligand-mediated 15 
dimerization, as well as the interactions mediated by the JAK2 PK domains and by the TM/JM domains, 
additively contribute to the total binding energy (Fig. 4C). Exploiting the availability of the constitutively 
dimerizing mutants TpoR W515L and JAK2 V617F, we obtained a comprehensive energetic picture for 
the different interactions (Fig. 4B). These moderate binding energies highlight the cooperativity of fine-
tuned subtle interactions regulating receptor dimerization. Our results indicate a low intrinsic dimerization 20 
affinity of the TpoR/JAK2 subunits, which is attributed to interactions between the JAK PK domains and 
the TM/JM region of the receptor (sites 1 and 2, respectively, in Fig. 4C). At physiological receptor 
densities at the plasma membrane, the total binding energy of these interactions is not sufficient to yield 
significant dimerization in the absence of ligand (Fig. 4C). Thus, the additional binding energy provided 
by ligand-mediated receptor cross-linking effectively shifts the equilibrium towards receptor dimers (Fig. 25 
4C). Likewise, a small increase in the binding energy of the intrinsic interactions upon single point 
mutations in the constitutive interacting sites can shift the equilibrium towards receptor dimers, as 
observed for TpoR W515L and JAK2 V617F. 
Weak intrinsic receptor dimerization correlates with constitutive activation 
These analyses predict a low intrinsic dimerization affinity for homodimeric class I cytokine receptors. To 30 
experimentally quantify the ܭ஽ଶ஽ of ligand-independent receptor dimerization, we employed single-
molecule FRET (smFRET) for direct detection of dimer formation via sensitized fluorescence. Thus, 
ligand-independent interaction of the receptors could be reliably detected and quantified even at relatively 
high receptor densities, which were not compatible with robust co-tracking analysis. Under these 
conditions, ligand-independent TpoR dimers could be observed in the presence of JAK2 wt, while much 35 
higher levels were observed in the presence of JAK2 V617F even at much lower receptor densities (Fig. 
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4D, fig. S9D and Movie S10). Substantially shorter smFRET trajectories were found for TpoR dimers in 
the presence of JAK2 wt compared to V617F suggesting rather transient dimerization under wt 
conditions. These observations support our model that the V617F mutation promotes receptor 
dimerization by stabilizing inter-JAK2 interactions. Relative dimerization increased in a receptor density-
dependent manner (Fig. 4E). By fitting the law of mass action, a two-dimensional ܭ஽ଶ஽ of (110 ± 60)/µm² 5 
was determined for TpoR in the presence of JAK2 wt compared to (5 ± 2)/µm² for JAK2 V617F, in good 
agreement with the values determined from co-locomotion analysis (Table S3). Similar results were 
observed with variants of EpoR and TpoR lacking the extracellular domains (EpoR-ΔECD and TpoR-
ΔECD, respectively) (fig. S9E, F and Table S3). These observations are in line with the activation of 
EpoR via synthetic cross-linkers (18, 38). Likewise, efficient activation of TpoR was achieved by 10 
dimerization through binding of a flexible cross-linker based on the NB against the mXFP-tag (Fig. 4G). 
Dimerizing and non-dimerizing oncogenic JAK2 mutations 
To further investigate the mechanism of signal activation we compared various oncogenic mutations in 
the JAK2 PK domain (Fig. 5A-D) (39). Three groups of mutations were chosen covering the FS-PK 
linker region (M535I, H538L and K539L; group I), residues in the proximity of the αC helix (H587N, 15 
C618R, N622I; group II), and a hotspot at the autoinhibitory PK-TK interface (40, 41) (I682F, R683G, 
F694L; group III) (Fig. 5A, B). While ligand-independent activation was confirmed for all these JAK2 
mutants, consistent TpoR dimerization was only observed for mutations within the first two groups (Fig. 
5A, B and fig. S10). In contrast, JAK2 mutations at the PK-TK interface (group III) yielded very low 
dimerization levels compared to their potent constitutive activation. This disconnect suggests gain-of-20 
function mutations in the PK cause JAK2 hyperactivity via distinct mechanisms: (i) loss of PK-mediated 
autoinhibition, facilitating trans-autophosphorylation of the TK domains in the context of receptor-JAK2 
monomers (group III); and (ii) stabilization of receptor-JAK2 dimers (groups I and II). Similar 
dimerization and activation patterns were observed for EpoR and GHR upon expression of selected 
mutants from groups I and II (Fig. 5C, D), supporting the common mechanistic basis for mutational 25 
hyperactivation of different receptors.  
Putative PK-PK interface mediates receptor dimerization and activation 
Interestingly, groups I and II both localize to a putative PK-PK interface (42, 43), which has been 
proposed based on the JAK1 PK crystal structure (44). This interaction is mediated by the N lobe of the 
PK domain, predominantly the αC-helix, and the linker connecting the FS and PK domains (42, 44, 45). 30 
We focused on residue E592, which is located at the center of the interface (Fig. 5B). In the context of 
TpoR, the mutation E592A did not alter basal (non-cytokine-mediated) JAK2 activation (32), however, 
activity increased upon introduction of a large hydrophobic residue (E592W, Fig. 5E and fig. S11A), and 
this correlated with ligand-independent dimerization of TpoR (Fig. 5F). In contrast, switching charge at 
this position (E592K) led to slightly reduced levels of activation and dimerization in the presence of Tpo 35 
(Fig. 5E, G), and substantially suppressed the hyperactivity of V617F (E592K/V617F), by reducing 
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dimerization (Fig. 5E, F and fig. S11A).  
TpoR density-dependent activation assays with JAK2 E592 mutants showed that E592W shifted the onset 
of constitutive activation to lower receptor densities compared to wt, while no constitutive activation was 
detectable for E592K (fig. S11B). These results highlight the changes in the intrinsic dimerization 
affinities resulting from mutation of the PK-PK interface. JAK2 E592W also constitutively dimerized and 5 
activated EpoR and GHR (Fig. 5C, D). Very similar patterns of dimerization and activation were found 
for the combination of JAK2 E592 mutants with EpoR using pSTAT5 as a functional readout (fig. S11C, 
D), highlighting the generic relevance of this JAK2 interaction site for homodimeric cytokine receptors. 
Overall, constitutive receptor dimerization and activation show a striking correlation for all mutants 
located in close proximity to the PK-PK interface (Fig. 5H), confirming the relevance of the PK-PK 10 
interface for JAK2 activation and dysregulation.  
Atomistic model of a transmembrane signaling complex 
Based on existing structural data and our experimental validation of a JAK2 PK-PK interface, we 
generated atomistic models of TpoR and EpoR dimers within membranes. Ligand-independent 
dimerization was modelled for JAK2 in complex with TpoR-ΔECD (Fig. 3B, Fig. 4E, F, fig. S9B, C). We 15 
performed multiple independent 1 µs all-atom molecular dynamics (MD) simulations for this system 
integrated into a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membrane (simulation 
system S1AA, Table S4, see SI for model system construction). For comparison, we generated a 
corresponding model of JAK2 bound to EpoR including the ectodomains dimerized by Epo (simulation 
systems 4AA and 5AA, Table S4, see SI for an independent construction of this model system). These 20 
systems represent very high receptor densities (~5000 receptors/µm²) and therefore we expect the 
equilibrium to be fully shifted towards the dimer even in the absence of the ligand. Despite starting with 
different complex geometries (see Methods section), these MD simulations converged into similar 
structural organization of JAK2 homodimers (Movie S11, Movie S12 and Fig. 6A, B, fig. S12A-C). In 
both cases, JAK2 adopts a stable extended orientation perpendicular to the membrane normal, with a 25 
slightly more tilted orientation in the EpoR complex (fig. S12B). The FERM domains were found to 
strongly interact with the inner leaflet of the lipid bilayer through the hydrophobic residue L224 and 
several positively charged residues from helix 3 in the F2 subdomain (Fig. 6C and fig. S13A-C), which 
may account for the decreased receptor diffusion constants in the presence of JAK2 (fig. S5E, S7E, S8G). 
These JAK2-lipid interactions stabilize the orientation of the complex with respect to the membrane. In 30 
contrast to the crystal structure of the JAK2 FS domains (used here as the starting geometry), which 
suggested that EpoR dimerization mediated by FS domains (46), we observed no stable contacts between 
the FS domains during our simulations. The contacts observed in the crystal structure predominantly 
dissociated during the simulations of the EpoR-JAK2 complex (Fig. S13D-F), and the residues involved 
in these contacts were found anchored into the membrane (Fig. S13G). Structural organization of JAK2 at 35 
the membrane was largely independent of the lipid composition as confirmed by atomistic MD 
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simulations with lipid mixtures comprising cholesterol and phosphatidyl-inositides in addition to POPC 
(simulation system S3AA, Table S4, fig. S12A-C, fig S13B, C). The tight coupling of the FS domains with 
the membrane enforces an appropriate orientation for optimal intermolecular PK-PK interaction of JAKs 
within the receptor dimers (Fig. 6A, left) involving several residues that we experimentally found to be 
implicated in dimerization (Fig. 5B). The TK domains were the most mobile parts of the otherwise stable 5 
complex (Fig. 6A, B, fig. S12, and Movies S11, S12). The simulation results support the schematic model 
shown in Fig. 4C, in which receptor dimerization shifts the cis PK-TK autoinhibitory interaction to a 
trans PK-PK interaction and thus liberates the TK domains.  
Membrane anchoring of the FERM domain regulates dimerization affinity 
MD simulations predicted an important role for FERM domain anchoring into the membrane via L224, a 10 
conserved hydrophobic residue within the JAK family (Leu in JAK1 and TYK2, Val in JAK3), which is 
surface-exposed in all FERM domain structures. To functionally test this prediction, we introduced a 
negative charge in this position (L224E). MD simulations confirmed a pronounced re-orientation of JAK2 
L224E compared to wt (simulation systems S14CG and S16CG, Table S4, Fig. 6D and fig. S14A, B). 
Strikingly, ligand-independent TpoR, EpoR and GHR dimerization and activation by JAK2 V617F was 15 
dramatically reduced upon introducing L224E (Fig. 6E and fig. S14C, D), supporting the key role of L224 
in orienting JAK2 at the membrane to allow productive PK-PK interactions. Cell micropatterning 
experiments revealed that the L224E mutation diminished without completely abrogating JAK2 binding 
to the receptors (fig. S14E). The binding stability of the FS interaction with TpoR at the plasma 
membrane was ~20-fold reduced as quantified by FRAP experiments (Fig. 6F). Ligand-induced receptor 20 
dimerization and activation was still observed for JAK2 L224E, though with reduced potency as 
compared to JAK2 wt (fig. S14F, G), which was also observed for the mutation E592K that directly 
compromised the PK-PK interface. Likewise, JAK2 L224E abrogated ligand-independent TpoR 
activation at elevated receptor densities (fig. S14H). JAK2 L224E also strongly reduced ligand-stimulated 
activation of EpoR and GHR (fig. S14G), supporting the key role of membrane anchoring across the 25 
homodimeric class I cytokine receptor family. Taken together, these results confirm that the L224E 
mutation does not compromise the structural integrity of JAK2, but rather destabilizes the intermolecular 
interaction between JAK2 monomers by altering the orientation of the receptor complex as predicted by 
our MD simulations.  
Oncogenic mutations alter and stabilize the receptor dimerization interface  30 
The PK-PK interaction in the signaling complex remained highly stable during the dimer simulations 
(systems S1AA-S5AA), corroborating the relevance of this interaction for the structural organization of the 
signaling complex. This stability arises from a combination of hydrophobic and polar interactions at the 
interface (Tables S5, S6). Interactions of certain key residues, such as E592 and F595, were found to be 
very stable, as exemplified by persistent contacts with their counterparts in the other monomer (Table S5). 35 
These results are consistent with a previous suggestion that the JAK2 V617F mutation promotes 
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activation by forming an intramolecular pi-stacking network between F617, F594 and F595 (45, 47). This 
hypothesis was tested by atomistic MD simulations for the isolated V617F mutant PK-PK dimer (systems 
S6AA and S7AA in Table S4). Comparison of the interacting residue pairs in these two cases (Table S6) 
highlights that some of the interactions at the interface are strikingly reorganized. Many of these 
interaction pairs involve a residue from the N-terminal linker (residues 526-539) connecting the PK 5 
domain to the FS domain. This linker has been shown previously to play a role in JAK2 activation (48). 
The reorganization of the interface leads to an increase in the number of intermolecular contacts for JAK2 
V617F compared to wt in systems S6AA and S7AA (Table S6). Free energy calculations conducted on JAK2 
wt (simulation S6AA) and V617F (simulation S7AA) systems using the MM-PBSA (Molecular Mechanics 
Poisson-Boltzmann Surface Area) scheme (49) displayed consistently lower binding free energy values 10 
for the mutated PK dimer compared to the wt (ΔΔGwt-VF = -32.7 ± 16.2 kJ/mol). Such free energy 
differences indicate stabilization of the V617F dimer over wild-type, as also observed in our experiments 
(see Fig. 4).  
To assess the role of the TpoR TM/JM segment, we simulated the receptor TM/JM helices (system S8AA, 
and S9AA in Table S4). They were found to align in a rather tilted orientation (helix tilt angle: 37 ± 2°), 15 
with W491 and W515 partitioning into the water/membrane interface as is typical for Trp residues. The 
W515L mutation increased the helix tilt to 41 ± 1º, likely imposing constraints on the TM domain that 
favor dimerization. Such involvement of the amphipathic JM segment in regulating TM interactions via 
tilting is qualitatively supported by spectroscopic studies on reconstituted TM-JM peptides (34). Coarse-
grained simulations (systems S10CG-S13CG, Table S4) corroborate this result, showing a highly tilted ‘X’-20 
shape to be the most stable TM dimer structure (Fig. S15, S16 and the Methods section).  
Discussion 
Our live-cell single-molecule imaging experiments establish that the prototypic homodimeric class I 
cytokine receptors EpoR, TpoR and GHR are monomeric in the basal state and are dimerized by their 
ligand. We therefore propose a molecular mechanism with ligand-induced dimerization as the 25 
fundamental switch initiating activation of these receptors, as originally proposed by Wells and coworkers 
(2). This mechanism contradicts the current view of pre-dimerized, inactive receptors that are activated by 
a ligand-induced conformational change (4). While we confirmed weak intrinsic receptor dimerization 
affinities that involve multiple interaction interfaces, we demonstrate that receptor pre-dimerization is 
negligible at physiological expression levels, yet accounts for a basal signaling activity. Thus, our 30 
quantitative studies did not provide any evidence for inactive receptor dimers, but rather revealed a strict 
correlation of receptor dimerization and activation. The weak intrinsic dimerization affinities, however, 
explain the observation of pre-dimerized receptors by techniques such as protein fragment 
complementation or cysteine crosslinking (7, 50, 51), which irreversibly crosslink weakly interacting 
subunits and thus shift the equilibrium towards receptor dimers. By contrast, the single-molecule assays 35 
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used in this study allow direct visualization and quantification of the monomer-dimer equilibrium at 
physiological receptor expression levels in living cells. Moreover, TIRF imaging in combination with 
extracellular posttranslational labeling ensures selective detection of receptor dimerization at the plasma 
membrane. The large fraction of the receptor that resides in endosomal vesicles may bias other methods 
of interaction analysis due to increased local concentrations during endocytic trafficking. Despite 5 
overexpression, we observed low cell-surface densities for these cytokine receptors, indicating that 
receptor cell-surface concentrations are highly regulated in order to minimize ligand-independent 
dimerization and activation.  
In addition to identifying ligand-induced dimerization as the key step of receptor activation, we have 
established the importance of the interaction between JAK PK domains within receptor dimers at the 10 
plasma membrane. So far, the critical regulatory function of the PK domain has been appreciated at the 
level of intramolecular inhibition of TK activity (40, 41), and the numerous constitutively JAK-activating 
mutations have been interpreted accordingly. Here, we demonstrate that a significant fraction of 
constitutively activating PK mutations, including JAK2 V617F, act by altering and strengthening the 
intermolecular interactions involving the PK-PK dimerization interface. These mutations drive 15 
cytoplasmic stabilization of receptor-JAK dimers, bypassing stabilization of dimers via extracellular 
cytokine binding. Our insights suggest that the design of agents that interfere with dimerization by direct 
or allosteric targeting of the PK-PK interface could improve therapeutic intervention for MPNs and 
potentially other hematological malignancies and immunological disorders. Equally, our work 
demonstrates that, although the extracellular domain is not required for oncogenic signaling, antagonism 20 
of receptor dimerization at the extracellular interface could be exploited to destabilize the active dimer, 
employing a strategy similar to that used for the modulation of EpoR signaling by engineered dimerizers 
(18, 38). 
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Figures 
 
Fig. 1 Receptor monomer-dimer equilibrium quantified by dual-color single-molecule imaging. (A) 
Cytokine receptor activation by ligand-induced dimerization (I) vs. ligand-induced conformational change 
of pre-formed dimers (II) schematically depicted for TpoR. Receptor subunits fused to mXFP were 5 
labeled with anti-GFP nanobodies (NB) conjugated to Rho11 (Rho11NB) and DY647 (Dy647NB), at equal 
concentrations. Receptor homodimers carrying both Rho11 and DY647 are identified by co-tracking 
analysis (stochastically only 50% of the entire dimer population). Co-expression of JAK2 wt and JAK2 
variants fused to mEGFP ensures unambiguous detection at the single cell level. (B) Individual mXFP-
TpoR in the plasma membrane of HeLa cells after labeling with Rho11NB and Dy647NB. The densities of 10 
molecules in each channel are depicted in the inset (calculated from 15 cells). The box plots indicate the 
data distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x interquartile range 
(whiskers). (C) TpoR tracking and co-tracking analysis shown for representative cells. Left: Trajectories 
(150 frames, ~4.8 s) of individual Rho11-labeled (red) and DY647-labeled (blue) TpoR before (top) and 
after (bottom) addition of Tpo. Right: Receptor dimers identified by co-locomotion analysis. (D, E) 15 
Single-step photobleaching observed for an individual TpoR dimer (red: Rho11; blue: Dy647) in the 
presence of Tpo (D) and intensity-time traces with the bleaching events indicated by arrows (E). (F) 
Spatial correlation of TpoR at single-molecule level by PICCS as schematically indicated in the inset. 
Representative results for a cell in the absence (blue) and presence of Tpo (green), respectively. 
  20 
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Fig. 2 Ligand-induced dimerization of TpoR, EpoR and GHR is regulated by JAK2. (A) Relative 
number of co-trajectories observed for positive and negative control proteins as well as for unstimulated 
TpoR, EpoR and GHR and after stimulation with the respective ligand with and without co-expression of 
JAK2. (B) Comparison of dimerization levels in the absence and presence of the JAK2 inhibitor 5 
ruxolitinib (left) and dimerization levels of TpoR Box1+2 mutant (right) co-expressed with JAK2 wt or 
V617F (VF). (C) Primary structure of JAK2 comprising FERM-SH2 (FS), pseudokinase (PK) and 
tyrosine kinase (TK) domains. Positions of the C-terminal truncations ΔTK and ΔPK-TK as well as key 
residues and mutations are highlighted. (D) Primary structure of TpoR including extracellular (EC), 
transmembrane (TM) and intracellular (IC) domains. The primary sequence of the TM domain (blue) 10 
followed by a functionally critical amphipathic motif (orange) and the intracellular domain (ICD) 
including the Box motifs (green) is shown below. The putative JAK2 binding sequence is indicated by a 
purple line. (E) Ligand-induced dimerization of TpoR co-expressed with different JAK2 variants as 
identified in panel C. Dashed lines mark the mean dimerization levels in the absence (grey) and presence 
of JAK2 wt (blue) or JAK2 V617F (magenta), respectively. Box plots in A, B and E indicate the data 15 
distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x interquartile range 
(whiskers). Each data point represents the analysis from one cell with a minimum of 10 cells measured for 
each condition. Significances of P > 0.05, P < 0.05, P ≤ 0.01 and P ≤ 0.001 are indicated by “n.s.”, *, ** 
and ***, respectively. 
  20 
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Fig. 3 Oncogenic JAK2 and TpoR mutants drive ligand-independent receptor dimerization. (A) Ligand-
independent dimerization of TpoR, EpoR and GHR by JAK2 V617F. Co-locomotion analysis of TpoR, 
EpoR and GHR co-expressed with either JAK2 or JAK2 V617F as well as a negative control (nc). (B) 
Ligand-independent dimerization by JAK2 V617F is driven by the pseudokinase domain. Co-locomotion 5 
analysis of indicated combinations of receptor and JAK2 variants. For ECD-TpoR, dimerization by 
JAK2 V617F was quantified by single-molecule FRET (see Movie S7). (C) Homo- and 
heterodimerization of cytokine receptors by JAK2 V617F. Left: homodimerization of IFNGR2; Right: 
heterodimerization of EpoR and TpoR that were orthogonally labeled via mXFP and SNAPf-tag, 
respectively (see Movie S8). (D) Ligand-independent dimerization of TpoR W515L (WL) in the absence 10 
and presence of different JAK2/TYK2 variants and JAK2 V617F (VF). Box plots in A-D indicate the data 
distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x interquartile range 
(whiskers). Each data point represents the analysis from one cell with a minimum of 10 cells measured for 
each condition. Significances of P > 0.05, P < 0.05, P ≤ 0.01 and P ≤ 0.001 are indicated by “n.s.”, *, 
** and ***, respectively. 15 
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Fig. 4 Energy landscape of TpoR dimerization and its mechanistic interpretation. (A) Determination of 
2D equilibrium constants from the dimerization levels observed under different conditions. Each dot 
corresponds to a dimerization experiment where the label denotes TpoR (wt or W515L-WL)/JAK2 (wt or 
V617F-VF)/ligand (+/-Tpo). The 2D law of mass action is depicted for a monomer(M)-dimer(D) 5 
equilibrium at a total receptor surface concentration of 2 µm-2 (blue) and 200 µm-2 (grey). Dimerization 
levels that cannot be unambiguously quantified by co-tracking are indicated by grey zones. (B) Semi-
quantitative energy diagram of the M-D equilibrium in the absence (-Tpo) and presence (+Tpo) of ligand 
as derived from (A). Experiments involving different TpoR/JAK2 combinations are depicted in different 
colors, and energy levels for determining different G are indicated. Energetic contributions G 10 
obtained for different combinations of components and mutations are listed in the table. (C) Proposed 
mechanism of homodimeric cytokine receptor activation deduced from live cell dimerization assays: in 
the absence of ligand (I), the basal level of dimerization caused by interactions mediated via the JAK2 PK 
domains (1) and TM/JM domains (2) is negligible because ܭ஽ଶ஽ substantially exceeds the receptor surface 
concentration in the plasma membrane. Ligand binding provides the additional binding energy (3) 15 
required to shift the equilibrium towards the dimeric state. Oncogenic mutations enhancing interactions 
(1) or (2), shift the equilibrium towards the dimeric state in a ligand-independent manner (II). (D-F) 
Intrinsic dimerization and activation of TpoR and EpoR. (D) Representative smFRET experiments with 
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TpoR co-expressed with JAK2-mEGFP wt (top) and V617F (bottom) showing single-molecule 
trajectories of the donor (red) as well as the acceptor upon direct excitation (blue) and via smFRET 
(magenta) detected within 150 frames (5 s). Total receptor densities were 1.2/µm² for JAK2 wt and 
0.4/µm² for V617F. Scale bar: 5 µm. (E) Relative ligand-independent dimerization levels as a function of 
receptor density for full-length TpoR in the presence of JAK2 wt and V617F and fit by the law of mass 5 
action for a monomer-dimer equilibrium (solid lines). Confidence intervals of the fit are indicated as grey 
zones. The dimerization curve in the presence of Tpo calculated from the corresponding ܭ஽ଶ஽ is shown for 
comparison (black dotted line). (F) Ligand-independent activation of STAT3 phosphorylation upon 
overexpression of TpoR and EpoR, respectively, together with wt JAK2 in HeLa cells. pSTAT3 and 
receptor cell surface densities were quantified by phospho-flow analysis. As a negative control, co-10 
expression of JAK2 was omitted. Error bars represent the standard error of the mean (SEM). (G) 
Activation of mXFP-TpoR by dimerization with an NB-based crosslinker that binds the mXFP-tag. For 
comparison, activation by Tpo in the presence and absence of TpoR (neg. control) is shown. 
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Fig. 5 Dimerization interface of JAK2 PK domains. (A) Ligand-independent dimerization of TpoR (top) 
and associated JAK2 phosphorylation (bottom) in the presence of oncogenic mutations within the JAK2 
PK domain. Residues are grouped and colored according to their location within the PK structure: FS-PK 
linker (blue); αC helix (magenta) and PK-TK interface (purple). (B) Putative intermolecular PK-PK 5 
interface derived from the MD simulations, with one PK domain colored orange and the other brown. The 
positions of the residues mutated in (A) are mapped onto the orange PK domain. Superimposed in cyan is 
the TK domain in its autoinhibitory configuration (intramolecular) relative to the orange PK domain; the 
TK domain would clash with the second (brown) PK domain. (C, D) Ligand-independent dimerization of 
EpoR (C) and GHR (D) (top) and associated JAK2 phosphorylation (bottom) for selected constitutively 10 
active JAK2 mutants. (E-G) Altering dimerization and activation by perturbation of the putative PK-PK 
interface via mutagenesis of E592. (E) Activity of different JAK2 mutants in HeLa cells stably expressing 
mXFP-TpoR. Phosphorylation of JAK2 and STAT5 in the absence of ligand (left) and after stimulation 
with Tpo (right) was probed by western blot. (F, G) Dimerization of TpoR associated with different JAK2 
mutants in the absence (F) and presence (G) of Tpo. (H) Correlation of receptor dimerization with 15 
activation for constitutively active JAK2 mutants (same color coding as in panel A). Error bars are 
omitted for clarity. In panels A, C, D, F and G, box plots indicate the data distribution of 2nd and 3rd 
quartile (box), median (line), mean (square) and 1.5x interquartile range (whiskers). Each data point 
represents the analysis from one cell with a minimum of 9 cells measured for each condition. 
Significances of P > 0.05 and P ≤ 0.001 are indicated by “n.s.” and ***, respectively.  20 
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Fig. 6 Structural organization of homodimeric cytokine receptor signaling complexes in the membrane. 
(A) Snapshot (t = 1 μs) from all-atom MD simulations of JAK2 bound to TpoR (transmembrane (TM) 
and intracellular (IC) domains) forming a homodimeric complex (system S1AA, Movie S11). JAK2 is 
colored green (FS), orange (PK), and cyan (TK). Protomer 1 is in dark colors with domains labeled, and 5 
protomer 2 is in light colors and unlabeled. The FS-PK and PK-TK linkers are colored gray. TpoR is 
colored magenta (bound to JAK2 protomer 1) and pink (bound to JAK2 protomer 2). POPC lipid 
molecules are colored off-white. The view in the right panel is rotated 90° with respect to that in the left 
panel, as indicated by the arrow. (B) Snapshot (t = 1 μs) from an all-atom MD simulation of a 
homodimeric complex of JAK2 bound to EpoR (residues P31-S335, system S4AA) in the presence of Epo 10 
(Movie S12). (C) Membrane binding of the F2 subdomain of FS stabilizes the orientation of JAK2 
relative to the membrane (enlarged view of the region indicated by the black rectangle in panel A). The 
side chains of L224 and the seven Lys and Arg residues in 3 that change orientation and flexibility upon 
interaction with the membrane are highlighted. (D-F) Functional role of L224 in TpoR dimerization and 
activation. (D) Representative orientation of JAK2 FS wt (left) and L224E (right) observed in MD 15 
simulations (systems S14CG and S16CG, respectively). Arrows indicate the orientation of the FS domain 
and its variation during the simulations. (E) Ligand-independent dimerization of TpoR (left) as well as 
JAK2 and STAT5 phosphorylation (right) observed for JAK2 wt and V617F upon combination with 
L224E. (F) Stability of JAK2 FS wt and L224E binding to TpoR probed by live cell micropatterning (fig. 
S14C) in combination with FRAP. Comparison of representative FRAP curves observed for JAK2 wt 20 
(green) and L224E (blue) and statistical analysis of dissociation rate constants (inset same color coding). 
The box plot indicates the data distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 
1.5x interquartile range (whiskers). Each data point represents the analysis from one cell with a minimum 
of 10 cells measured for each condition. Significances of P > 0.05 and P ≤ 0.001 are indicated by “n.s.” 
and ***, respectively. 25 
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Materials and Methods 
Plasmids 
For single-molecule fluorescence microscopy, a non-fluorescent (Y66F) variant of 
monomeric green fluorescent protein (mXFP) was N-terminally fused to human TpoR, human 
EpoR and rabbit GHR, respectively. These constructs as well as indicated truncations or 
mutations were inserted into a modified version of pSems-26m (Covalys) which includes the N-
terminal signal sequence of Igκ followed by a hemagglutinin (HA)-tag upstream of the mXFP tag 
(pSems-leader). E3-tagged or E3-tag-mXFP-tagged receptors were cloned accordingly using the 
21 amino acid E3-tag as described previously (22). For negative control experiments, a model 
transmembrane protein, comprised of an N-terminal monomeric enhanced green fluorescent 
protein (mEGFP) tag linked to an artificial transmembrane domain (ALA)7KSSR was inserted 
into the same vector. For positive control experiments maltose binding protein (MBP) was 
inserted between mEGFP and the artificial transmembrane domain for dimerization via a 
monoclonal antibody against MBP. The effective degree of cell surface labeling achieved by dye-
conjugated nanobodies was determined using either HaloTag-mEGFP-IFNAR2 or SNAPf-
mEGFP-IFNAR1. For cellular micropatterning, the receptor genes N-terminally fused to HaloTag 
and mTagBFP were inserted into pSems-leader (HaloTag-mTagBFP-TpoR, HaloTag-mTagBFP-
EpoR and HaloTag-mTagBFP-GHR, respectively). As negative controls, TpoR truncated after 
R514 (TpoR-514Δ) as well as TpoR with mutations in the box 1 and 2 motifs (TpoR Box1+2: 
W529A, S531A, P533A, D534A, E569A, I570A and L571A) to abolish JAK binding were 
cloned accordingly. For the comparison of mXFP-tagged and untagged receptors, EpoR, TpoR 
and rGHR including their original N-terminal signal sequences as well as a C-terminal 2A self-
cleaving peptide (P2A) (52) followed by mTagBFP including a nuclear localization (NLS) 
sequence were cloned into the pSems-26m backbone. Truncations of the extracellular domains of 
TpoR (upstream of Y483) and EpoR (upstream of P245) were created by PCR according to 
standard protocols.  
All mutants or truncations of JAK2 or TYK2 were C-terminally fused to mEGFP and 
inserted into pSems-26m. JAK2 was truncated after I827 (JAK2 ΔTK) or E543 (JAK2 ΔPK-TK) 
to remove the JH1 (tyrosine kinase, TK) domain or both JH1 and JH2 (pseudokinase, PK) 
domains, respectively. TYK2 was similarly truncated after Y896 (TYK2 ΔTK) or I588 (TYK2 
ΔPK-TK). Point mutations within the receptor and the kinases were generated by PCR according 
to standard protocols (and see below). 
For activity assays by western blot and phospho-flow cytometry, untagged JAK2 wt and 
mutants were cloned into pIRES2-EGFP (Clontech). Point mutants of JAK2 and TYK2 were 
generated by site-directed polymerase chain reaction (PCR) mutagenesis using either 
CloneAmp™ HiFi PCR Premix (TaKaRa/Clontech) or Phusion HotStart Flex 2X Master Mix 
(NEB/ThermoFisher) and overlapping primers. Reactions were set up in a final volume of 10 µL 
containing 4 ng template plasmid DNA, and a final concentration of 60 nM of each primer. When 
using Phusion HotStart Flex 2X Master mix, DMSO was included at a final concentration of 3 % 
(v/v). For CloneAmp™ HiFi polymerase, the following reaction conditions were used: 98 ºC for 
30 sec, then 18 cycles of 98 ºC for 10 sec, 55 ºC for 30 sec then 72 ºC for 150 or 300 sec, and 
finally 72 ºC for 600 sec. For Phusion HotStart Flex polymerase, the following reaction 
conditions were used: 98ºC for 60 s, then 25 cycles of 98ºC for 15 s then 72ºC for 330 s, and 
finally 72ºC for 600 s. Template DNA was removed by digestion with DpnI (NEB, 0.2 U, 90 min 
at 37ºC followed by heat inactivation for 20 min at 80ºC), and 1 µL PCR reaction was then used 
to transform 25 µL chemically competent E. coli DH5α (Invitrogen/ThermoFisher). Plasmids 
were isolated from overnight cultures of single colonies using a QIAprep spin miniprep kit 
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(QIAGEN), and mutations confirmed by Sanger sequencing (Eurofins Genomics) across the 
entire JAK2/TYK2 open reading frame (ORF). Multiple mutants were generated by using an 
appropriate, sequence-verified single or double mutant as template for a second or third round of 
PCR mutagenesis. For use in transfection experiments, sequence-verified plasmids were 
amplified using a GenElute™ HP Plasmid MidiPrep Kit (Sigma Aldrich) according to the 
manufacturer’s instructions. DNA concentrations were determined using a NanoDrop 2000 
(ThermoScientific), and integrity of plasmid DNA verified by agarose gel electrophoresis.  
The features and applications of different receptor and JAK constructs are summarized here: 
Denomination Construct (residues) Description and application 
mXFP-TpoR pSems-leader-HA-mXFP-
TpoR (25-635) 
mXFP-tagged TpoR for single molecule 
microscopy 
mXFP-ΔECD-TpoR pSems-leader-HA-mXFP-
TpoR (482-635) 
mXFP-tagged TpoR lacking the 
extracellular domain for single molecule 
microscopy 
mXFP-EpoR pSems-leader-HA-mXFP- 
EpoR (25-508) 
mXFP-tagged EpoR for single molecule 
microscopy 
mXFP-EpoR-ΔECD pSems-leader-HA-mXFP-
EpoR(244-508) 
mXFP-tagged EpoR lacking the 
extracellular domain for single molecule 
microscopy 
mXFP-rGHR pSems-leader-HA-mXFP- 
rGHR (19-638) 
mXFP-tagged rabbit GHR for single 
molecule microscopy 
TpoR pSems-TpoR (1-635)-P2A-
NLS-BFP 
Untagged TpoR as control for activity 
analysis by phospho-flow cytometry 
EpoR pSems-EpoR (1-508)-P2A-
NLS-BFP 
Untagged EpoR as control for activity 
analysis by phospho-flow cytometry 
E3-TpoR pSems-leader-HA-E3-tag- 
TpoR(25-635) 
E3-tagged TpoR for single molecule 
microscopy 
E3-EpoR pSems-leader-HA-E3-tag- 
EpoR (25-508) 
E3-tagged EpoR for single molecule 
microscopy 
E3-mEGFP-EpoR pSems-leader-HA-E3-tag-
mEGFP- EpoR (25-508) 
E3- and mEGFP-tagged EpoR for single 
molecule microscopy 
mEGFP-TMD pSems leader-HA-mEGFP-
(ALA)7KSSR 
Negative control for single molecule 
microscopy 
mEGFP-MBP-TMD pSems leader-HA-mEGFP-
MBP-(ALA)7KSSR 
Positive control for single molecule 
microscopy 
HaloTag-mEGFP-
IFNAR2 
pSems-leader-HA-HaloTag-
mEGFP IFNAR2(27-515) 
IFNAR1 with N-terminal HaloTag and 
mEGFP for quantifying the DOL at single 
molecule level 
SNAPf-mEGFP-
IFNAR1 
pSems-leader-HA-HaloTag-
mEGFP IFNAR1(28-557) 
IFNAR1 with N-terminal SNAPf and 
mEGFP for quantifying the DOL at single 
molecule level 
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Denomination Construct Description 
HaloTag-mTagBFP-
TpoR 
pSems-leader-HA-HaloTag- 
mTagBFP-TpoR(25-635) 
TpoR with N-terminal HaloTag and 
mTagBFP as bait for cell micropatterning 
HaloTag-mTagBFP-
TpoR-514Δ 
pSems-leader-HA-HaloTag- 
mTagBFP-TpoR(25-514) 
TpoR lacking the entire intracellular 
domain with N-terminal HaloTag and 
mTagBFP as bait for cell micropatterning 
HaloTag-mTagBFP-
EpoR 
pSems-leader-HA-HaloTag-
mTagBFP-EpoR(25-508) 
EpoR with N-terminal HaloTag and 
mTagBFP as bait for cell micropatterning 
HaloTag-mTagBFP-
rGHR 
pSems-leader-HA-HaloTag-
mTagBFP-rGHR(19-638) 
GHR with N-terminal HaloTag and 
mTagBFP as bait for cell micropatterning 
mXFP-IFNGR2 pSems leader HA mEGFP-
Y66F IFNGR2(28-337) 
mXFP-tagged IFNGR2 for single 
molecule microscopy 
JAK2-mEGFP pSems-JAK2 (1-1132)-
mEGFP 
Full-length JAK2 with C-terminal mEGFP 
for single molecule microscopy 
JAK2 pIRES2-EGFP JAK2 (1-1132)  Full-length JAK2 for activity assays by 
western blot 
JAK2-ΔTK-mEGFP pSems JAK2 (1-827)-mEGFP 
 
JAK2 lacking the TK domain for single 
molecule microscopy  
JAK2-ΔPKTK-
mEGFP 
pSems-JAK2-(1-543)-mEGFP JAK2 lacking TK and PK domains for 
single molecule microscopy and cell 
micropatterning 
TYK2-mEGFP pSems-TYK2 (1-1187)-
mEGFP 
Full length TYK2 with C-terminal 
mEGFP for single molecule microscopy 
TYK2-ΔTK-mEGFP pSems-TYK2 (1-896)-mEGFP Tyk2 lacking the TK domain for single 
molecule microscopy 
TYK2-ΔPKTK-
mEGFP 
pSems-TYK2 (1-588)-mEGFP TYK2 lacking TK and PK domains for 
single molecule microscopy and cell 
micropatterning 
 
Protein expression and purification 
For cell surface labeling, the anti-GFP nanobody (NB) “enhancer” was used, which binds 
mEGFP with a 0.3 nM binding affinity (53). NB was cloned into pET-21a with an additional 
cysteine at the C-terminus for site-specific fluorophore conjugation in a 1:1 
fluorophore:nanobody stoichiometry. Furthermore, a (PAS)5 sequence to increase protein stability 
and a His-tag for purification were fused at the C-terminus. Protein expression in E. coli Rosetta 
(DE3) and purification by immobilized metal ion affinity chromatography was carried out by 
standard protocols. Purified protein was dialyzed against HEPES pH 7.5 and reacted with a two-
fold molar excess of DyLight 800 (ThermoFisher, DY800) maleimide (ThermoFisher), DY-
647P1 (DY647) maleimide (Dyomics), ATTO 643 (AT643) maleimide and ATTO Rho11 
(Rho11) maleimide (ATTO-TEC GmbH), respectively. After 1 h, a 3-fold molar excess (with 
respect to the maleimide) of cysteine was added to quench excess dye. Protein aggregates and 
free dye were subsequently removed by size exclusion chromatography (SEC). A labeling degree 
of 0.9-1:1 fluorophore:protein was achieved as determined by UV/Vis spectrophotometry. The 
NB-based dimerizer was obtained by reacting purified NB with 1,11-bismaleimido-
triethyleneglycol (ThermoFisher #22337) in a 2:1 ratio in HEPES pH 7.5 followed by SEC. 
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Recombinant Epo, GH and ECD-GHR were produced in Hi5 insect cells using baculoviral 
infection according to standard protocols. Recombinant human Tpo was a gift from Don Foster 
(Zymogenetics, Seattle, WA). For fluorescence labeling, 56 µM Tpo was incubated with 53 µM 
Alexa Fluor 647 (AF647) NHS ester (Invitrogen; stock solution at 2 mg/mL in dimethyl 
sulphoxide (DMSO, Sigma)) in a final volume of 150 µL 0.53 X phosphate buffered saline (PBS; 
Sigma) supplemented with 27 mM NaHCO3 (Fluka) for 1 h at 22 ºC with shaking. Unreacted dye 
was removed by applying the reaction mixture to a 0.5 mL 7 kDa molecular weight cutoff 
(MWCO) Zeba™ spin desalting column (Invitrogen), and the dye: protein ratio determined 
spectrophotometrically. This yielded AF647-Tpo with an average dye: protein ratio ~ 0.7. In a 
second step, in order to increase the dye:protein ratio, 27 µM AF647-Tpo was incubated with 
53 µM AF647 NHS ester under the reaction conditions described above. Unreacted dye was 
removed as described above, except that the spin column was pre-equilibrated with 1 X PBS 
before use. This yielded AF647-Tpo with a dye:protein ratio ~2:1, and this was used for 
subsequent experiments. The integrity and homogeneity of the labelled Tpo were confirmed by 
sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) and SEC-multi-angle 
laser light scattering (MALS). Bovine GH was purchased from Prospecbio. YbbR-tagged human 
GH wt and G146R were expressed in E. coli and refolded from inclusion bodies by standard 
protocols. After purification by anion exchange and size exclusion chromatography, proteins 
were enzymatically labeled using DY647 and DY547 maleimide (Dyomics) conjugated to 
Coenzyme A as described previously (54). Labeling degree was determined by UV/Vis 
spectrophotometry. 
A K4 peptide including a C-terminal Cys residue was custom synthesized by Genscript 
Biotech Co. Rho11-maleimide (ATTO-TEC GmbH) and DY647 maleimide, respectively were 
coupled under aqueous conditions at pH 6.8. The conjugates Rho11K4 and DY647K4 were purified 
by reversed phase HPLC and their identity was confirmed by MALDI. 
Western blot, phospho-flow cytometry staining and antibodies 
HeLa clones were serum starved for 16 hours prior to cytokine stimulation for 10 minutes. 
Cells were then lysed in Nonidet P40 (NP-40) lysis buffer (50 mM 
tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 10 mM β-glycerolphosphate, 1 mM Na3VO4, 10 mM 
NaF) containing 1% protease inhibitors (Sigma-Aldrich #P8340). Denatured proteins were 
fractionated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. 
Protein expression was detected by incubating with anti-phospho JAK2 (Y1007/8; #3771), anti-
JAK2 (#3230), anti-phospho STAT5 (Y694; #9359), anti-STAT5 (#9363), anti-HA (#3724) 
followed by anti-rabbit-HRP (#7074) or anti- actin-HRP (#5125) (all Cell Signaling 
Technologies) and visualized by chemiluminescent detection reagent (ECL-prime; GE Healthcare 
#29018903). The phosphorylated JAK2 (pJAK2) was quantified using ImageJ/Fiji (52). Each 
lane from the blot was selected by drawing a box with similar dimensions and the intensity 
measured using the 'Analyze/ Gel/ GelAnalyzerOptions' in Fiji. pJAK2: JAK2 intensity ratios 
were obtained and normalized to the corresponding JAK2 wt sample and then plotted using 
GraphPad Prism v8.0. 
For quantifying STAT3 and STAT5 by flow cytometry (Cytoflex S, Beckman Coulter), 
HeLa, HEK293 and HeLa clones stably expressing mXFP-tagged receptors were first detached 
using PBS + EDTA (2 mM). Detached cells could be used for several assays (see below). Cells 
were immunostained after fixation (2% paraformaldehyde) and permeabilization in ice-cold 
methanol (100% v/v). Anti-pSTAT5 (Cell Signaling Technologies, #9365) or anti-pSTAT3 
(Biolegend, #651007) antibodies conjugated to Alexa Fluor 647 were used at a 1:100 dilution. 
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Mean fluorescence intensity (MFI) values were plotted together with standard error of the mean 
(SEM). The following experimental conditions were used in different types of experiments: 
 Dose-response curves: Cells were stimulated with indicated concentrations of ligand for 
15 min at 37°C. 
 Cytokine stimulation and inhibitor treatment: Cells were transfected with the indicated 
receptor and/or JAK2 constructs using the polyethyleneimine (PEI, Polysciences Inc, # 
233966) method according to standard protocols. As a negative control, cells were treated 
with the JAK inhibitor Tofacitinib (3 µM for 30 min at 37°C) before cytokine stimulation 
(15 min at 37°C). 
 Receptor density-dependent basal pSTAT activity: PEI-transfected cells expressing 
mXFP-tagged receptors were cell surface stained with DY800NB (10 nM) for 20 min on ice. 
JAK2 expression was detected using the EGFP signal. Cell surface receptor densities were 
quantified via DY800 fluorescence. The fluorescence intensity was translated into 
absolute receptor densities by calibrating the DY800NB signal using a stable cell line with 
known cell surface density determined by single molecule imaging (2.5 receptors/µm2). 
Quantification of TpoR cell surface expression by flow cytometry 
Ba/F3-parental, Ba/F3-MPL, HeLa, HeLa-MPL, UT7 and UT7-Tpo cells were plated at 
1x105 cells per well in a total volume of 25 µL, and treated with increasing concentrations of 
AF647-Tpo (dye:protein 2.0) for 1 hr at RT whilst shaking at 600 rpm. Cells were washed three 
times in FACS buffer (0.5% w/v BSA, 0.05% v/v sodium azide in PBS) and analysed by flow 
cytometry on a Cytoflex LX. In these experiments, a concentration of 50 μg/mL (~680 nM) 
AF647-Tpo was shown to be saturating. The mean fluorescence intensity (MFI) values at 
saturating AF647-Tpo for cell lines expressing MPL were corrected by background subtraction 
using the values for the corresponding parental (non-MPL expressing) cell line at the same 
AF647-Tpo concentration.  
Cell culture for microscopy 
HeLa cells were cultivated at 37°C and 5% CO2 in MEM’s Earle’s medium with stable 
glutamine supplemented with 10% fetal bovine serum (FBS), non-essential amino acids and 
HEPES buffer without addition of antibiotics. For microscopy experiments, confluent cells were 
trypsinated and transferred to a 60 mm cell culture dish (1:10 dilution) and transiently transfected 
via calcium-phosphate-precipitation according to standard protocols (55). Transfected cells were 
transferred onto 25 mm glass coverslips (1:20 dilution) coated with a poly-L-lysine-graft-
(polyethylene glycol) copolymer functionalized with RGD to minimize non-specific binding of 
fluorescent NBs (56). Single-molecule imaging experiments were conducted 48 h post 
transfection after mounting the coverslips into custom-designed microscopy chambers with a 
volume of 1 mL. For experiments with GHR, cells were kept in serum-reduced (2% FBS) media 
overnight, supplemented with 300 nM of the soluble ECD of human GHR in order to scavenge 
bovine GH. 4 hours before imaging, cells were washed 4x with PBS, and coverslips were 
transferred to clean 3 cm dishes containing serum-free media. For cellular micropatterning, 24-
36 hours after transfection cells were plated on chemically modified cover glasses for 15-20 
hours with medium containing penicillin and streptomycin (PAA Laboratories).  
Single-molecule fluorescence imaging 
Single-molecule imaging experiments were conducted by total internal reflection 
fluorescence (TIRF) microscopy with an inverted microscope (Olympus IX71) equipped with a 
triple-line total internal reflection (TIR) illumination condenser (Olympus) and a back-
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illuminated electron multiplied (EM) CCD camera (iXon DU897D, Andor Technology) as 
described in more detail previously (18, 57). A 150 × magnification objective with a numerical 
aperture of 1.45 (UAPO 150 × /1.45 TIRFM, Olympus) was used for TIR illumination of the 
sample. All experiments were carried out at room temperature in medium without phenol red, 
supplemented with an oxygen scavenger and a redox-active photoprotectant to minimize 
photobleaching (58). For cell surface labeling of mXFP-tagged receptors, DY647- (or AT643-) 
and Rho11-labeled NBs were added to the medium at equal concentrations (2 nM each) that 
ensured > 90% binding given the 0.3 nM binding affinity. After incubation for at least 5 min, 
image acquisition was started with the labeled NBs kept in the bulk solution during the whole 
experiment in order to ensure high equilibrium binding. Negative and positive control proteins for 
co-localization were labeled under the same conditions. Under these conditions, an effective 
labeling efficiency of ~70% is achieved for mXFP-tagged cell surface proteins as determined by 
single-molecule co-locomotion analysis of model proteins fused to either mEGFP and SNAPf or 
HaloTag (SNAPf-mEGFP-IFNAR1 & HaloTag-mEGFP-IFNAR2) as previously described (57). 
E3-tagged receptors were labeled by incubating with 10 nM Rho11K4 or DY647K4 for 10 min at 
room temperature. After washing with 3 mL medium, imaging experiments were immediately 
started. HaloTag-fusion proteins were labeled with 50 nM HaloTag-Ligand 
Tetramethylrhodamine (HTL-TMR, Promega) and SNAPf-tagged proteins were labeled with 
80 nM SNAP-Surface DY647 (New England Biolabs, Inc.) at 37°C for 15 min and washed 5 
times with pre-warmed PBS to remove unreacted dyes. Dimerization of cytokine receptors was 
probed before and after incubation with 5 nM of the corresponding ligand. Dimerization of the 
positive control mEGFP-MBP-TMD was induced using 20 nM monoclonal antibody against 
MBP (Santa Cruz Biotechnology, Inc.sc-13564). Pharmacological inhibition of JAK activity was 
achieved using the JAK inhibitor Ruxolitinib (Adooq Bioscience). Ruxolitinib was added to the 
culture medium at 3 µM 4h prior to imaging experiments.  
For single molecule co-localization and co-tracking experiments, orange (Rho11 and TMR) 
and red (DY647 and AT643) emitting fluorophores were simultaneously excited by illumination 
with a 561 nm laser (CrystaLaser) at 0.95 mW (~32 W/cm2) and a 642 nm laser (Omicron) at 
0.65 mW (~22 W/cm2). Fluorescence was detected using a spectral image splitter (DualView, 
Optical Insight) with a 640 DCXR dichroic beam splitter (Chroma) combined with the bandpass 
filter 585/40 (Semrock) for detection of Rho11/TMR and 690/70 (Chroma) for detection of 
DY647/AT643 dividing each emission channel into 512 x 256 pixels. Image stacks of 150 frames 
were recorded for each cell at a time resolution of 32 ms/frame. For PAINT experiments, 10 nM 
of a low-affinity GFP binder labeled with AT643 was added to the medium. To obtain long-
timescale receptor distribution at the cell surface, 16000 frames were recorded over 8.5 min. 
Single molecule FRET (smFRET) was probed by alternating laser excitation (ALEX). To this 
end, mXFP-tagged receptors were labeled with Rho11 and AT643 as described above. Two-color 
image acquisition was performed with alternating excitation at 561 nm and at 642 nm frame-by-
frame at a frame rate of 50 Hz using a fast (EM) CDD camera (iXon Ultra 897, Andor 
Technology). Thus, a total time resolution of 25 frames/s was achieved, which was sufficient for 
reliable tracking. 
Single-molecule analyses 
Single-molecule localization was carried out using the multiple-target tracing (MTT) 
algorithm (59) and tracking was performed using the u-track algorithm (60). Single molecule 
PAINT images were reconstructed from emitters localized within 16000 frames. Diffusion 
constants were determined by mean square displacement analysis within a time window of 
320 ms (10 frames). For co-tracking analysis, immobile molecules were identified by 
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spatiotemporal cluster analysis (61) and removed from the dataset (typically ~15-20% of all 
localizations) prior to quantifying diffusion and dimerization because this fraction is biased by (i) 
labeled NBs non-specifically adsorbed onto the coverslip surface and (ii) endosomes located 
close to the plasma membrane. Receptor dimerization was quantified based on sequential co-
localization and co-tracking analysis as described in detail recently (57): after aligning Rho11 and 
DY647 channels with sub-pixel precision by using a spatial transformation based on a calibration 
measurement with multicolor fluorescent beads (TetraSpeck microspheres 0.1 µm, Invitrogen), 
individual molecules detected in both spectral channels of the same frame within a distance 
threshold of 100 nm were considered co-localized. For single-molecule co-tracking analysis, the 
MTT algorithm was applied to this dataset of co-localized molecules to reconstruct co-
locomotion trajectories (co-trajectories) from the identified population of co-localizations. For the 
co-tracking analysis, only co-trajectories with a minimum of 10 consecutive steps (320 ms) were 
considered. This cut-off was determined based on systematic analysis of a negative control 
experiment with non-interacting model transmembrane proteins (57) in order to minimize 
background from random co-localization (Fig. S5A). The relative fraction of co-tracked 
molecules was determined with respect to the absolute number of trajectories from both channels 
and corrected for dimers stochastically double-labeled with the same fluorophore species as 
follows: 
 	ܣܤ∗ 	ൌ ஺஻ଶൈቂቀ ಲಲశಳቁൈቀ ಳಲశಳቁቃ Eqn. 1 
 ݎ݈݁.		ܿ݋ െ ݈݋ܿ݋݉݋ݐ݅݋݊ ൌ 	 ଶൈ஺஻∗ሺ஺ା஻ሻ Eqn. 2 
where A, B, AB and AB* are the numbers of trajectories observed for Rho11, DY647, co-
trajectories and corrected co-trajectories, respectively. Box plots were used for visualization and 
indicate the data distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5× 
interquartile range (whiskers). Each data point represents the analysis from one cell with a 
minimum of 10 cells measured for each condition. Statistical significances were calculated by 
unpaired t-tests. 
For heterodimerization experiments of mXFP-TpoR and SNAPf-EpoR, the relative fraction 
of dimerized receptors was calculated from the number of co-trajectories relative to the number 
of TpoR trajectories as EpoR was expressed in moderate excess (~2 fold). 
Particle image cross correlation spectroscopy (PICCS) was applied for co-tracking-
independent quantification of co-localized molecules (62). PICCS analysis was performed as 
described previously (23) to determine the correlated fraction α of particles in channel A which 
are co-localized with particles in channel B: 
 ܥ௖௨௠ሺݎሻ 	ൌ 	ߙ ௖ܲ௨௠ሺݎሻ 	൅	ܿ௖௛௔௡௡௘௟஻ 	 ∙ 	ߨݎ² Eqn. 3 
For randomly distributed particles without a correlated fraction α, the function is linear at 
increasing search area r² with the slope given by the density of particles in channel B. The offset 
of this linear term corresponds to the correlated fraction α. 
For quantifying receptor dimerization by smFRET, molecules were localized in the 
sensitized acceptor fluorescence channel. False-positive smFRET signals were removed by co-
localization with directly excited acceptor signals. For this purpose, the FRET and acceptor 
channels were co-localized with a threshold of 200 nm to compensate for temporal shift due to 
alternating excitation. Based on the co-localization data the relative dimerization was determined 
and corrected for dimers stochastically double-labeled with the same fluorophore as described for 
co-tracking experiments above. 
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Calculation of equilibrium constants and free energy contributions ΔΔG 
The two-dimensional equilibrium dissociation constants (ܭ஽ଶ஽) were calculated according to 
the law of mass action for a monomer-dimer equilibrium: 
 ܭ஽ଶ஽ ൌ ሾெሿ
మ
ሾ஽ሿ ൌ
ሺሾெሿబିଶሾ஽ሿሻమ
ሾ஽ሿ  Eqn. 4 
Where [M] and [D] are the concentrations of the monomer and the dimer, respectively, and 
[M]0 is the total receptor concentration. The relative dimerization levels Drel were plotted as a 
function of ܭ஽ଶ஽ according to the physically relevant solution of the square equation: 
 ܦ௥௘௟ ൌ ଶሾ஽ሿሾெሿబ ൌ
ଶ
ሾெሿబ ቎
ቆሾெሿబା಼ವ
మವ
ర ቇ
ଶ ቏ െ
ඨቆሾெሿబା಼ವ
మವ
ర ቇ
మ
ସ െ
ሾெሿబమ
ସ  Eqn. 5 
assuming an average [M]0 of 2 molecules/µm². Measured relative dimerization levels from 
co-tracking experiments were normalized to the relative dimerization level of the positive control 
(0.26) prior to calculating the corresponding ܭ஽ଶ஽: 
 ܭ஽ଶ஽ ൌ ଶ൫ଵିଶ஽ೝ೐೗ା஽ೝ೐೗
మ ൯ሾெሿబ
஽ೝ೐೗  Eqn. 6 
Free energy contributions were calculated from the changes in ܭ஽ଶ஽ according to: 
 ߂߂ܩ ൌ െܴܶ ൈ ݈݊ ቀ௄మ௄భቁ  Eqn. 7 
with the universal gas constant R and the absolute temperature T. 
The relative dimerization levels ܦ௥௘௟ from smFRET experiments were calculated from the 
number of molecules detected in the sensitized fluorescence channel and the total number of 
molecules detected by direct acceptor excitation. For each sampled cell, the 2D dissociation 
constant (ܭ஽ଶ஽) was determined using the law of mass action (Eqn. 6) given the observed total 
receptor density and relative dimerization level taking the effective DOL of 70% into account. 
From the pooled experiments an average dissociation constant as well as its standard error could 
be estimated. The final dose response curves were then generated by plugging the respective 
average dissociation constant and its 95% confidence bounds into Eqn. 5. 
Cell micropatterning and image analysis 
Micropatterned functionalized surfaces for live cell micropatterning were fabricated by 
microcontact printing as described previously (63). Poly(dimethylsiloxane) (PDMS) stamps were 
generated from basic elastomer (Sylgard 184, Dow Chemicals) mixed with curing agent (Dow 
Chemicals) in a 10:1 ratio, and applied to a silicon master at 80°C overnight. The silicon master 
containing an array of lines with a width of 5 µm, a spacing of 10 µm and a depth of 3 μm was 
generated by photolithography using a custom designed beam mask (nb technologies GmbH). 
Standard glass coverslips for fluorescence microscopy were cleaned in a plasma cleaner for 
10 minutes, followed by inking of the stamp with 0.5 mg/mL poly-L-lysine-graft-poly (ethylene 
glycol) (PLL-PEG) conjugated with the HaloTag ligand (PLL-PEG-HTL) (64) in PBS buffer for 
10 minutes. For PLL-PEG-HTL transfer, stamps were placed onto the glass coverslips for 
10 minutes to generate HTL patterns. After removing the stamps, the coverslips were incubated 
with a mixture of 0.002 mg/mL PLL-PEG conjugated with the peptide RGD (PLL-PEG-RGD) 
(63) and 0.1 mg/mL of methoxy-terminated PLL-PEG (PLL-PEG-MeO) in PBS buffer for 1 min 
to backfill the uncoated area to allow cell adhesion. The surface was then rinsed in MilliQ water 
and dried with nitrogen. 
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For micropatterning experiments, TIRF microscopy was performed using an inverted 
microscope (Olympus IX81) equipped with a 4-line TIRF condenser (Olympus TIRF 4-Line 
LCl), a CMOS camera (ORCAFlash 4.0, 2048×2048 pixel from Hamamatsu) and lasers at 
405 nm (100 mW), 488 nm (150 mW), 561 nm (150 mW) and 640 nm (140 mW). A 60× 
objective with a numerical aperture of 1.49 (UAPON 60×/1.49, Olympus) or a 100× objective 
with a numerical aperture of 1.49 (UAPON 100×/1.49, Olympus) was used for TIRF excitation. 
The excitation beam was reflected into the objective by a quad-band dichroic mirror 
(zt405/488/561/640rpc) and the fluorescence was detected through a quadbandpass filter 
(BrightLine HC 446/523/500/677). For multicolor experiments, a fast emission filter wheel 
equipped with suitable emission filters (BrightLine HC 445/45, BrightLine HC 525/50, 
BrightLine HC 600/37 and BrightLine HC 697/58) was utilized to avoid spectral cross-talk. Data 
acquisition was performed with the acquisition software Olympus CellSens 2.2. Image analysis 
and image processing were performed using ImageJ/ Fiji (NIH, Bethesda, MD). Image processing 
comprised cropping, scaling, rotation as well as adjustment of brightness and contrast levels. 
Stabilities of JAK-receptor complexes were determined by fluorescence recovery after 
photobleaching (FRAP) experiments as described previously (65). A rectangular region of 
interest (ROI) within the bleached area of the pattern and a rectangular or circular ROI within the 
bleached area but outside the patterned area were chosen for obtaining intensity values per pixel 
over time, respectively. Corrected FRAP curves were determined using the following equation: 
 ܨሺݐሻ ൌ ൫ிೃೀ಺೔೙ೞ೔೏೐ିி೚೑೑ೞ೐೟൯ି൫ிೃೀ಺೚ೠ೟ೞ೔೏೐ିி೚೑೑ೞ೐೟൯ቀಷೝ೐೑షಷ೚೑೑ೞ೐೟ቁ
ቀಷೝ೐೑,బషಷ೚೑೑ೞ೐೟ቁ
  Eqn. 8 
with FROI,inside and FROI,outside being the fluorescence intensities inside and outside the pattern, 
respectively, within the bleached spot. Fref is the fluorescence intensity of an unbleached ROI 
inside the micropattern, and Fref,0 is the fluorescence intensity of this ROI before the bleaching 
experiment. Fref was implemented as a normalization factor to correct for photobleaching during 
FRAP experiments. The offset intensity (Foffset) was determined from an ROI outside of the cell 
and was subtracted from all intensity values. Image analysis to obtain corrected FRAP curves was 
performed using a Matlab script. The corrected FRAP curves F(t) were fitted by a mono-
exponential function. Two-sample Kolmogorov-Smirnov-Tests were performed in order to 
calculate statistical significances. 
Atomistic simulation models for JAK2/TpoR 
TpoR-ΔECD:JAK2 dimer in a lipid bilayer: System S1AA (Table S4) is an all-atom (AA) 
model of the JAK2/TpoR homodimer (Fig. 6A, left panel), lacking the ectodomains of TpoR. 
Two of the known dimerization interfaces; the PK/PK interface of JAK2 (inferred by homology 
with the X-ray crystal structure of JAK1) and the TM/TM interface of TpoR (initial structure 
obtained from our simulations S10CG-S13CG, see description of coarse-grained simulations 
below), were used to guide the construction of this dimer structure. We first energy minimized 
the X-ray crystal structure of the FERM-SH2 domain (residues 37-514) of JAK2 (PDB id: 
4Z32)(21) and then homology modeled the JAK2 PK/PK dimer (residues 526-810) based on the 
X-ray crystal structure of the JAK1 PK/PK dimer (PDB id: 4L00) (44). Next, we linked the 
PK/PK dimer to the FERM-SH2 domains. In this structure, we aligned the FERM-SH2 domain in 
an ‘upright’ orientation, with the F2 subunit of the FERM sub-domain facing the membrane, 
since it is known to contain an amphipathic region that most likely mediates membrane 
interactions (66). This orients the SH2 sub-domains toward the cytosol, and these were linked to 
the PK domains through an unstructured linker segment. Since we did not detect intermolecular 
interactions between the FERM-SH2 domains, they were placed apart from each other. To 
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complete the full JAK2 dimer structure, we homology modeled the TK domains (residues 811-
1132) based on the TYK2 TK domain within the crystal structure of the TYK2 PK-TK fragment 
(PDB id: 4OLI) (41), and concatenated the structures to the PK/PK dimer. For the PK-TK 
linkage, a flexible and unstructured linker segment was chosen, since in electron microscopy 
imaging of JAK1 these domains have been observed to exhibit extensive intersegmental 
flexibility (67), and since the TK domains require sufficient flexibility to cross-phosphorylate 
each other. The assembled JAK2-TpoR dimer complex was then embedded into a pure POPC 
lipid bilayer using the CHARMM-GUI membrane builder (68). 
System S2AA is similar to the TpoR-JAK2 dimer complex, but with the V617F mutation. 
System S3AA is analogous to the S1AA model but embedded into a multicomponent lipid bilayer, 
containing 70 mol% POPC and 30 mol% cholesterol in its extracellular (EC) leaflet, and 
65 mol% POPC, 30 mol% cholesterol, and 5 mol% phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2) in its cytosolic (IC) leaflet. 
1:2:2 Epo:EpoR:JAK2 complex in a lipid bilayer: Systems S4AA and S5AA comprise a 
dimer model of JAK2-EpoR, which was constructed through the following steps. First, we 
extracted a dimer structure from the tetrameric JAK2 FS-EpoR structure (PDB:6E2Q) and 
completed the missing loops in both JAK2 and EpoR. The relative orientation of the FERM-SH2 
domains corresponding to chains A and C (or B and D) in the 6E2Q structure is close to that of 
our JAK2-TpoR model (systems S1AA-S3AA), so we linked the PK and TK domains to the dimeric 
FS-EpoR structure in a similar fashion to systems S1AA-S3AA. This places the positively charged 
patches on the FERM sub-domain close to the membrane: a crucial feature for the proper function 
of the receptor complex. We then built the TM dimer of EpoR based on the structure of the EpoR 
TM monomer (PDB:2MV6). The TM/TM interface of EpoR was modeled based on limited 
structural homology to the TpoR TM/TM interface. We therefore generated two different dimer 
structures: II-shaped corresponding to System S4AA and X-shaped corresponding to System S5AA. 
Lastly, we linked the structure of the EpoR ectodomains in complex with Epo (PDB:1CN4) to the 
TM helices to produce the full model of the JAK2-EpoR-Epo dimer (EpoR residues 31-335). 
JAK2 PK dimers: Systems S6AA and S7AA are all-atom models of the isolated JAK2 PK/PK 
dimer corresponding to wild-type and V617F mutant, respectively. The simulation models for 
these protein complexes were constructed as described above using homology modeling. The 
mutation was introduced into both of the PK subunits using the MODELLER tool (69). These 
systems were used to explore the importance of the PK/PK interface, and thus were simplified, 
lacking the rest of the dimer structure (i.e., the TpoR, JAK2 FERM-SH2, and JAK2 TK 
domains). These isolated PK/PK domain systems were also used to evaluate the binding affinity 
of the PK/PK interface for different mutants using the MM-PBSA (Molecular Mechanics 
Poisson-Boltzmann Surface Area) scheme (70). Binding affinities were evaluated with the 
g_mmpbsa tool (49), which calculates the enthalpic component of the free energy, assuming 
changes in the entropic component to be relatively minor. The analysis was conducted at 310 K 
and the solute dielectric constant was set to 2.5. Snapshots for the analysis were taken at 1 ns 
intervals. Data were calculated after RMSD-based clustering of the snapshots using a cutoff of 
0.25 nm to select the two largest clusters from each simulation. 
TpoR TM monomers: Systems S8AA and S9AA are all-atom models of the wt and W515L 
mutant of the TpoR TM monomers (residues 486-519), respectively. These systems were used to 
study the tilting of the TM helix in a membrane environment. 
TpoR-ΔECD dimers in a lipid bilayer: To construct the TM-TM dimer interface in the 
JAK2-TpoR homodimer, we modeled the TM domain of TpoR (residues 486-519) based on its 
structural homology to the TM helix of EpoR (PDB id: 2MV6) (71). Since the dimer structure of 
the TM helices in TpoR is currently unknown, we used coarse-grained (CG) MARTINI 
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simulations to identify the TM-TM dimer structure (systems S10CG-S13CG (Table S4); see 
description of coarse-grained simulations below). Guided by these CG simulations, an X-shaped 
dimer structure was selected. This CG dimer structure along with the lipid bilayer was then fine-
grained to atomistic representation using one of the CHARMM-GUI tools (72). Finally, we 
homology modeled the intracellular (IC) part of TpoR (residues 520-578) and its binding to the 
two FERM-SH2 domains of the JAK2 dimer on the basis of the X-ray crystal structures of the 
closely related JAK1 FS-IFNLR1 (PDB id: 5IXD) (73) and TYK2 FS-IFNAR1 complexes (PDB 
id: 4PO6) (74). 
Coarse-grained MARTINI simulations  
TpoR-ΔECD dimers in a lipid bilayer: To determine the structure of the TM dimer of 
TpoR, we simulated two TM helices in a POPC bilayer using the CG MARTINI model (75). The 
systems studied correspond to wt (S10CG) and the W515L mutant (S11CG), respectively (Table 
S4). The use of CG models enabled modeling over the timescales required to observe 
spontaneous dimerization in a membrane environment. In both cases, the helices readily 
dimerized into two different structures: a parallel II-shape and a tilted X-shape. The dimer 
structures that resulted from the simulations were analyzed and classified according to their 
residue-by-residue contact maps. Figs. S11 and S12 show the contact maps for the resulting 
dimers (”X” or ”II”) in both mutant and wt cases, respectively.  
In the wt CG simulations (system S10CG), seven out of 10 simulations resulted in a parallel 
II-shaped dimer (see Fig. 1), while the rest were X-shaped dimers (see Fig. S15). In the W515L 
mutant (system S11CG), four out of 10 simulations resulted in an X-shaped dimer while three of 
the 10 simulations predicted a parallel orientation. Additionally, three simulations showed no 
dimerization due to insufficient diffusion of the helices. The contact maps (Figs. S15 and S16) 
illustrate the shape of the dimer and reveal specific interactions in each dimer form. In the X-
dimer, for example, H499-H499 interactions are always the most prevalent, while the II-dimer 
shows contacts throughout the length of the helix. Furthermore, the wt dimers interact via their 
amphipathic domains, while the W515L mutants do not.  
To gain further support for the choice of TM-TM dimer structure, we extracted the most 
common structures from the last frames of the CG simulations (t = 20 μs) of the systems S10CG 
and S11CG: the X-shaped mutant dimer and the II-shaped wt dimer. We then mutated these TM 
helices such that the X-shaped W515L mutant became an X-shaped wt (system S12CG) and the II-
shaped wt became a II-shaped W515L mutant (system S13CG). In the simulations of these 
systems, we found that four of the II-shaped W515L dimers rapidly converted into the X-shape, 
whereas in the wt case the X-shape persisted. These data suggest that the X-shaped structure is 
the more stable dimer type, especially in the W515L mutant. It was therefore fine-grained to an 
all-atom description to complete the atomistic model of the JAK2/TpoR homodimer (system 
S1AA). 
TpoR-ΔECD:JAK2 FERM-SH2 monomers in a lipid bilayer: Systems S14CG-S16CG 
comprise a monomeric FERM-SH2 domain bound to the TM and IC domains of TpoR and 
embedded into a POPC/POPS bilayer (IC leaflet contains 10 mol% of POPS, see Table S4), such 
that S14CG is a TpoR:JAK2 wt complex, S15CG is a TpoR:JAK2 L224A complex, and S16CG is a 
TpoR:JAK2 L224E complex. These coarse-grained systems were used to analyze the effect of 
mutation of the membrane-anchoring L224 residue at longer timescales (20 µs). 
Molecular dynamics simulations 
Every simulation was initiated with the CHARMM-GUI portal (72, 76). This included the 
CG models and mutations of the TpoR TM helices in the systems S10CG-S16CG. Interactions in 
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the simulation systems were described using the all-atom CHARMM36 force field (77, 78) or the 
CG MARTINI model (75) (see Table S4). In the all-atom systems, we used the TIP3P water 
model (79). In the CG simulation models, water was described in terms of the MARTINI water 
beads. In both all-atom and CG descriptions, sodium and chloride ions were added to reach 
physiological concentration (150 mM), and to neutralize the charge of the system. In the all-atom 
systems, the ion interactions followed the general CHARMM ion parameters (80). Every system 
was simulated through several repeats to improve sampling (Table S4). The total time scales 
covered in the simulations were 30 μs (all-atom) and 800 μs (CG simulations). 
Simulation Parameters: We employed the GROMACS simulation software package (81) 
to run the simulations. Systems were first energy-minimized and equilibrated for 100 ps with the 
solute molecules restrained (76). Following equilibration, we conducted production runs as 
described in Table S4. These runs were conducted using the leap-frog integrator with a time step 
of 2 fs. Periodic boundary conditions were used in all three dimensions. The Verlet lists (82) kept 
track of atomic neighbors and the LINCS algorithm maintained all bonds constrained (83). 
Electrostatic interactions were evaluated with the smooth particle-mesh Ewald (PME) algorithm 
(84) of the order of 4. Lennard-Jones interactions were cut off at 1.2 nm. Temperature was fixed 
to a physiological 310 K with the Nosé-Hoover thermostat (85, 86). Solute and solvent atoms 
were coupled separately with a time constant of 1 ps. Pressure was coupled isotropically for 
membrane-exclusive systems and semi-isotropically for the membrane-inclusive systems using 
the Parrinello-Rahman barostat (87) with a time constant of 4 ps. At the beginning of each 
simulation replicate, random initial velocities were assigned for the atoms from the Boltzmann 
distribution. Simulation trajectories were saved every 100 ps. For other parameters, GROMACS 
5.1.4 defaults (78, 81) were used. The CG systems were simulated using the “New-RF” 
simulation parameters available in Ref. (88). 
Analysis: Tilt angles between the JAK2 FS domain and the membrane normal were 
calculated using the gmx_bundle tool within GROMACS by defining a vector between the Cα 
atoms of residues 223 and 492. These residues were chosen to span the principal axis of the FS 
domain from the membrane anchor within the F2 sub-domain to the tip of the SH2 domain. 
Fraction of coverage by solute (where solute is protein or lipid) for the individual domains of 
JAK2 within the receptor-JAK2 complex models was obtained by: (i) calculating the solvent 
accessible surface area (SASA) for each JAK2 domain using the GROMACS gmx-sasa tool; (ii) 
dividing the SASA by the total surface area of each domain to yield the solvent accessible 
fraction; (iii) subtracting this value from 1. 
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Fig. S1. 
Binding of mEGFP-tagged JAK variants to class I cytokine receptors in the plasma membrane 
probed by live cell micropatterning. (A) Cartoon depicting cell micropatterning: cells expressing 
TpoR N-terminally fused to the HaloTag and mTagBFP (HaloTag-mTagBFP-TpoR) were 
cultured on glass coverslips with micropatterned HaloTag ligand (HTL). Upon HaloTag binding 
to HTL, spatial reorganization of HaloTag-mTagBFP-TpoR (bait) in the plasma membrane is 
observed. Binding of cytosolic, mEGFP-tagged JAK (prey) proteins to micropatterned TpoR is 
quantified from the relative contrast of bait and prey proteins. (B) Live cell micropatterning 
experiments with different micropatterned receptor variants as bait proteins (cyan) and cytosolic 
mEGFP-tagged (green) JAK variants. Scale bar: 10 µm. DIC: differential interference contrast. 
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Fig. S2. 
Functionality of mXFP-tagged receptors and JAK2 constructs. (A) Expression of mXFP-TpoR, 
mXFP-EpoR and mXFP-GHR in HeLa cells detected by western blot. (B) Phosphorylation of 
JAK2 and STAT3 in HeLa clones stably expressing the indicated receptor as detected by western 
blot. (C) Activity of JAK2-mEGFP (mEGFP) and non-tagged JAK2 (pIRES). HEK293 cells 
transiently co-transfected with TpoR and JAK2 wt (blue) or V617F (magenta), respectively, were 
analyzed by phospho-flow cytometry for pSTAT5 without stimulation and after incubating with 
5 nM Tpo for 15 min. (D) Ligand-induced STAT3 phosphorylation in cells expressing TpoR, 
EpoR and GHR as quantified by phospho-flow cytometry. HeLa cells stably expressing the 
respective receptor were co-transfected with JAK2 and pSTAT3 was quantified in the absence 
(light color) and presence (dark color) of ligand. (E) STAT3 phosphorylation in cells expressing 
TpoR and EpoR in the absence and presence of the JAK inhibitor tofacitinib. (F) Comparison of 
STAT5 activation by mXFP-tagged vs. non-tagged TpoR and EpoR. Error bars in panels C-F 
represent the standard error of the mean (SEM).  
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Fig. S3. 
Bell-shaped dose-response curves for STAT5 phosphorylation and receptor dimerization. (A) 
Quantification of phosphorylated STAT5 by phospho-flow cytometry upon ligand stimulation of 
HeLa clones stably expressing TpoR (top), EpoR (middle) and GHR (bottom). Error bars 
represent standard deviations (SD) from three independent experiments. As a control, parental 
HeLa cells were analyzed under the same conditions. (B) Ligand concentration-dependent 
dimerization of TpoR (top), EpoR (middle) and GHR (bottom). Box plots indicate the data 
distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x interquartile range 
(whiskers). Each data point represents the analysis from one cell with a minimum of 10 cells 
measured for each condition. 
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Fig. S4. 
Spatiotemporal organization of TpoR in the plasma membrane. (A) Single-step photobleaching of 
unstimulated TpoR (see Movie S6). Diffusion of individual mXFP-TpoR (Rho11NB) was followed 
by single particle tracking at elevated laser intensity (561 nm; ~2 mW ≈ 70W/cm²). Trajectories 
(left), intensity traces (right) and image representation as a pseudo-3D kymograph (center) is 
shown for seven color-coded particles. (B) Super-resolution images depicting the spatiotemporal 
cell surface distribution of TpoR in the absence of ligand localized over 16,000 frames. Scale bar: 
5 µm. (C) Effective labeling of mEGFP-tagged proteins at the cell surface by anti-GFP 
nanobodies as quantified by single-molecule co-locomotion analysis. Degree of labelling (DOL) 
for Rho11NB was assessed by co-locomotion analysis of SNAPf-mEGFP-IFNAR1 labeled with 
Rho11NB and SNAP-Surface 647. DOL for Dy647NB was assessed by co-locomotion analysis of 
Halo-mEGFP-IFNAR2 labeled with Dy647NB and HaloTag ligand-conjugated 
tetramethylrhodamine (HTL-TMR). Box plots indicate the data distribution of 2nd and 3rd quartile 
(box), median (line), mean (square) and 1.5x interquartile range (whiskers). Each data point 
represents the analysis from one cell. (D) Quantification of TpoR cell surface expression levels in 
different cell lines by flow cytometry and staining with fluorescence-labeled Tpo (50 μg/mL). 
Error bars represent standard deviations (SD) from three independent experiments. 
  
  20 
 
Fig. S5. 
Quantitative TpoR dimerization analysis. (A) Co-locomoting fractions obtained upon using 
different numbers of consecutive steps as a cut-off for co-tracking analysis. Comparison for 
mEGFP-MBP-TMD in the absence (negative control, black squares) and presence (positive 
control, red circles) of a monoclonal anti-MBP IgG (mAb) and enlarged view of the dashed 
rectangle showing the negative control (right). Error bars represent standard deviations (SD) from 
>10000 particles. (B) Dual-step photobleaching within a TpoR trajectory indicating dimer 
formation in the presence of Tpo. Scale bar: 1 µm. (C) Receptor dimerization detected by single 
molecule FRET: increase in Rho11 fluorescence (FRET donor) upon photobleaching of DY647 
(FRET acceptor) within individual receptor dimers. Mean normalized intensity from 14 
trajectories aligned for photobleaching of DY647 at frame number 40. The average increase in 
donor intensity of 75% corresponds to a FRET efficiency of 43%. (D) Comparison of the 
diffusion constants for mXFP-tagged and E3-tagged TpoR in the absence and presence of Tpo as 
obtained from single molecule trajectories. Diffusion constants obtained from co-trajectories are 
highlighted in magenta. (E) Diffusion of mXFP-tagged TpoR co-expressed with JAK2 wt (black) 
and V617F (violet), respectively. Diffusion constants obtained from co-trajectories are 
highlighted in magenta. Box plots indicate the data distribution of 2nd and 3rd quartile (box), 
median (line), mean (square) and 1.5x interquartile range (whiskers). Each data point represents 
the analysis from one cell with a minimum of 10 cells measured for each condition. Significance 
of P ≤ 0.01 is indicated by **.  
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Fig. S6. 
Spatial receptor organization in the plasma membrane quantified by particle image cross-
correlation spectroscopy (PICCS). (A, B) PICCS analysis for a dual-color labeled model 
transmembrane protein in the absence (A) and presence (B) of a dimerizing monoclonal antibody. 
(C, D) PICCS analysis for unstimulated (C) and Tpo-stimulated (D) TpoR. green dots: 
cumulative correlation function obtained from single-molecule localizations. Black line: linear 
contribution of the cumulative correlation function. Purple line: cumulative correlation after 
subtraction of the linear term (black line). The curves show representative data from individual 
cells. Full statistical analysis is summarized in Table S2. 
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Fig. S7. 
Dimerization and spatiotemporal organization of EpoR. (A) Dual color co-tracking of EpoR in 
the absence (top) and presence (bottom) of Epo. Trajectories (150 frames, ~4.8 s) of individual 
Rho11NB-labeled (red) EpoR, DY647NB-labeled (blue) EpoR, and co-trajectories (magenta) are 
shown for a representative cell. (B) Super-resolution images depicting the spatiotemporal cell 
surface distribution of EpoR in the absence of ligand localized over 16,000 frames. Scale bar: 
5 µm. (C) Comparison of the diffusion constants for mXFP-tagged, E3-tagged and E3-mXFP-
tagged EpoR in the absence and presence of Epo. Diffusion constants obtained from co-
trajectories are highlighted in magenta. (D) Dimerization of EpoR by Epo wt (red) and S126E 
(blue) applied at two different concentrations. (E) Diffusion of mXFP-tagged EpoR co-expressed 
with JAK2 wt (black) and V617F (purple), respectively. Diffusion constants obtained from co-
trajectories are highlighted in magenta. Box plots indicate the data distribution of 2nd and 3rd 
quartile (box), median (line), mean (square) and 1.5x interquartile range (whiskers). Each data 
point represents the analysis from one cell with a minimum of 10 cells measured for each 
condition. Significances of P ≤ 0.01 are indicated by **.  
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Fig. S8. 
Spatiotemporal organization and dynamics of GHR. (A) Dual color co-tracking of GHR in the 
absence (top) and presence (bottom) of GH. Trajectories (150 frames, ~4.8 s) of individual 
Rho11NB-labeled GHR (red), DY647NB-labeled GHR (blue), and co-trajectories (magenta) are 
shown for a representative cell. (B) Super-resolution images depicting the spatiotemporal cell 
surface distribution of GHR in the absence of ligand localized over 16,000 frames. Scale bar: 5 
µm. (C) Diffusion constants of mXFP-tagged (black) and E3-tagged (green) GHR in the absence 
and presence of GH. For comparison, diffusion of fluorescently-labeled GH wt and G146R bound 
to non-tagged GHR expressed in HeLa cells was determined (blue). Diffusion constants obtained 
from co-trajectories are highlighted in magenta. (D) Serum-starving is critically required for 
background-free dimerization experiments with GHR. Co-locomotion analysis of GHR 
transfected cells was measured for unstimulated cells and after stimulation with the indicated 
ligand (5 nM, 10 min) either for cells cultured in FBS-containing media (10%) or after serum 
starvation and scavenging of residual bovine GH with the ectodomain of GHR (-). Wt JAK2-
mEFGP was co-expressed in all tested conditions. (E) Comparison of GHR dimerization by GH 
wt (red) and G146R (blue) at two different concentrations. (F) Density of endogenous GHR in 
HuH7 cells compared to stably transfected HeLa cell lines as quantified by incubating with 
10 nM DY648GH. 10 nM DY648GH mixed with 100 nM unlabeled GH was used as a negative 
control. (G) Diffusion of mXFP-tagged GHR co-expressed with JAK2 wt (black) and V617F 
(purple), respectively. Diffusion constants obtained from co-trajectories are highlighted in 
magenta. Box plots indicate the data distribution of 2nd and 3rd quartile (box), median (line), mean 
(square) and 1.5x interquartile range (whiskers). Each data point represents the analysis from one 
cell with a minimum of 10 cells measured for each condition. Significances of P > 0.05, P ≤ 0.01 
and P ≤ 0.001 are indicated by “ns”, ** and ***, respectively.  
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Fig. S9. 
Ligand-independent dimerization and activation of TpoR in the presence of JAK2 V617F. (A) 
TpoR dimerization detected by single-molecule (sm) FRET: increase in Rho11 fluorescence 
intensity upon photobleaching of DY647 within individual receptor dimers, imaged at elevated 
laser intensities to induce acceptor photobleaching. Relative changes in donor intensities for 
ligand-independent TpoR dimers in the presence of JAK2 V617F (magenta curve) and for TpoR 
co-expressed with wt JAK2 and dimerized by Tpo (blue curve). Mean normalized intensities 
calculated from ≥10 trajectories that were aligned for photobleaching of DY647 at frame number 
40 are shown. Error bars represent standard deviations (SD). (B) Ligand-independent 
dimerization of TpoR, TpoR-ECD and EpoR-ECD in the presence of JAK2 V617F quantified 
by smFRET. (C) Ligand-independent activation of TpoR-ECD (blue) and EpoR-ECD by 
JAK2 wt and V617F. Error bars represent the standard error of the mean (SEM). Significances of 
P ≤ 0.01 and P ≤ 0.001 are indicated by ** and ***, respectively. (D) Representative smFRET 
experiments with TpoR co-expressed with JAK2-mEGFP wt (top and middle rows) and V617F 
(bottom row) showing single molecule trajectories of the donor (red) as well as the acceptor upon 
direct excitation (blue) and via smFRET (magenta) detected over 150 frames (5 s). Total receptor 
densities were 1.2/µm² (top row) and 0.6/µm² for JAK2 wt (middle row) as well as 0.4/µm² for 
JAK2 V617F (bottom row). Selected regions with co-trajectories are enlarged in the panel at the 
right. Scale bar: 5 µm. (E, F) Ligand-independent dimerization of TpoR-ΔECD (E) and EpoR-
ΔECD (F) in the presence of JAK2 wt and V617F observed by smFRET. The law of mass action 
for a monomer-dimer equilibrium was fitted (solid lines) with the confidence intervals indicated 
  25 
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Fig. S10. 
Activation of TpoR, EpoR and GHR by oncogenic JAK2 mutants located in the PK domain. (A, 
B) Comparison of ligand-independent dimerization (A) and JAK2 phosphorylation (B) observed 
upon co-expression of JAK2 wt and oncogenic mutants with TpoR. In panel A, the box plot 
indicates the data distribution of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x 
interquartile range (whiskers). Each data point represents the analysis from one cell with a 
minimum of 10 cells measured for each condition. In panel B, the grey columns indicate mean 
intensity values from four independent phospho-JAK2 blots, which are represented as data points. 
Error bars show standard error of the mean (SEM) from four independent experiments. (C, D) 
Representative western blots showing ligand-independent JAK/STAT phosphorylation observed 
for JAK2 wt and selected dimerizing mutants co-expressed with EpoR (C) and GHR (D). 
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Fig. S11. 
Role of the putative JAK2 PK-PK interface probed by mutating E592. (A) Phosphorylation of 
JAK2 wt and mutants V617F (VF), E592K (EK), EK/VF and E592W (EW) co-expressed with 
TpoR in the absence (left) and presence (right) of Tpo as determined densitometrically from 
western blots. Error bars represent standard deviations (SD) from three independent experiments. 
(B) Receptor density-dependent activation of TpoR by JAK2 wt, E592W and E592K in the 
absence of Tpo. Error bars represent the standard error of the mean (SEM). (C, D) Ligand-
independent EpoR dimerization (C) and STAT5 phosphorylation (D) induced by JAK2 
mutations. STAT5 phosphorylation was probed by phospho-flow cytometry of HeLa cells stably 
expressing EpoR. JAK2 wt and mutants were transiently expressed and pSTAT5 was quantified 
in the absence (-) and presence (+) of Epo. The box plot in panel C indicates the data distribution 
of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x interquartile range (whiskers). 
Each data point represents the analysis from one cell with a minimum of 10 cells measured for 
each condition. Significance of P ≤ 0.001 is indicated by ***. Error bars in panel D represent the 
standard error of the mean (SEM). 
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Fig S12. 
Comparison of the atomistic MD simulations for TpoR and EpoR under different conditions. (A) 
Root-mean-square deviations (RMSDs) of different protein domains and whole proteins observed 
in different MD simulations: TpoR/JAK2 wt in POPC (blue); TpoR/JAK2 V617F in POPC (red); 
EpoR/JAK2 wt in POPC (green); TpoR/JAK2 wt in POPC/PI(4,5)P2/cholesterol (orange). TM: 
transmembrane helix residues (TpoR: 492—513; EpoR: 251—273); JM: juxtamembrane region 
residues (TpoR: 514-517; EpoR: 273-277); Cyt.: the remaining cytoplasmic residues; Rec.: entire 
receptor. Error bars represent standard errors of the mean (SEM). (B) Tilt angle of the FERM-
SH2 domain with respect to the membrane normal. We calculated this tilting angle by defining a 
vector between the Cα atoms of residues 223 and 492 and comparing it to the membrane normal 
with the GROMACS tool gmx bundle. These residues were chosen to span the principal axis of 
the FS domain from the membrane-anchoring part of the F2 FERM subdomain to the tip of the 
SH2 domain. The EpoR systems display an orientation of the FERM-SH2 domain that is tilted an 
additional 20—30 degrees compared to the TpoR systems due to a more tilted initial dimer pose 
in the 6E2Q template structure. Same color coding as in A. (C) Fraction covered by solute for 
three JAK2 domains (FS (top); PK (middle); TK (bottom)) in four different systems. This 
estimates how much the surface of each domain is covered by solute (i.e. protein or membrane 
components). The data are obtained by combining simulation replicates of systems S1AA-S5AA. 
Same color coding as in A. 
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Fig. S13. 
JAK2 organization at the membrane explored by MD simulations. (A) Membrane anchoring of 
JAK2 FERM F2 subdomain (system S1AA) induces a conformational reorganization of L224 
(green). (B, C) Probability of contacts between residues of the F2 subdomain of FERM and 
different structural elements of the lipid bilayer, as obtained for a neutral pure POPC membrane 
(B) and for a negatively charged membrane (65 mol% POPC, 30 mol% cholesterol and 5 mol% 
phosphatidylinositol-4,5-bisphosphate) (C). Data are calculated from systems S1AA and S3AA, 
respectively. Error bars represent the standard error of the mean (SEM). (D-G) Behavior of the 
membrane proximal EpoR residues (I282 and W283) responsible for the dimerization of JAK2 
FS domains in the PDB:6E2Q structure. (D, E) Snapshots at the (D) beginning (t = 0) and (E) end 
(t = 1000 ns) of a simulation. EpoR W283 (yellow) and JAK2 W298 (red) are highlighted. The 
arrows highlight the dissociation of EpoR W283 from the dimerization pocket. The JAK2 PK and 
TK domains have been omitted for clarity. (F) Minimum distance histogram calculated between 
EpoR W283 and JAK2 W298 and color-coded to indicate the simulation time. The initial state 
corresponds to the highest probability peak at a distance of ~0.4 nm. (G) Numbers of contacts 
between the membrane proximal EpoR residues (I282 and W283) and POPC lipids during the 
simulation. Errors represent standard error of the mean (SEM). Data are calculated from systems 
S4AA and S5AA, comprising four simulation replicates.  
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Fig. S14. 
The mutation L224E in the JAK2 FERM domain affects structural organization and activity. (A, 
B) Orientation of the JAK2 FERM-SH2 domain at the plasma membrane upon introduction of the 
JAK2 mutations L224A and L224E as determined from MD simulations (A) as outlined by the 
arrows in the snapshots from MD simulations of JAK2 wt (left, system S14CG) and L224E (right, 
system S16CG). Arrows indicate the orientation of the FS domain and its variation during the 
simulations. (C, D) Ligand-independent dimerization (C) and JAK2 phosphorylation (D) upon 
co-expression of EpoR and GHR, respectively, with different JAK2 mutants. (E) Receptor 
binding of JAK2 wt and L224E confirmed by cell micropatterning. Representative images 
obtained for JAK2 FS wt and L224E fused to mEGFP interacting with micropatterned TpoR, 
EpoR and GHR, respectively, and comparison of the contrast (bottom). The contrast obtained for 
the negative control with mEGFP as prey protein (“-“) is indicated by the dotted line. (F) 
Dimerization of TpoR co-expressed with different JAK2 mutants in the absence and presence of 
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Tpo. (G, H) Activity of JAK2 L224E probed by phospho-flow cytometry of pSTAT3. (G) 
Ligand-induced STAT3 phosphorylation in cells co-expressing TpoR, EpoR or GHR with JAK2 
wt or L224E. Light color: no stimulation; dark color: stimulation with 10 nM cytokine for 15 
min. (H) Receptor-density dependent STAT3 phosphorylation upon co-expression of TpoR with 
JAK2 wt and L224E in the absence of Tpo. Box plots in C, E and F indicate the data distribution 
of 2nd and 3rd quartile (box), median (line), mean (square) and 1.5x interquartile range (whiskers). 
Each data point represents the analysis from one cell with a minimum of 10 cells measured for 
each condition. Significances of P ≤ 0.001 are indicated by ***. Error bars in panels G and H 
represent the standard error of the mean (SEM).  
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Fig. S15. 
Contact profiles in the TM-JM segments of wild-type TpoR dimers (calculated from the system 
S10CG). Residues from helix 1 are shown along the y-axis and those from helix 2 along the x-axis. 
Color bar indicating the average number of contacts is shown on the right. Contacts were 
calculated with the GROMACS tool gmx mindist: a contact was counted if two residues were 
within a distance of 0.6 nm. The upper left panel indicates the prevailing dimer configuration in 
the simulation. ”II” denotes a parallel configuration for the two TM helices, whereas ”X” 
represents tilted TM helices in the dimer. 
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Fig. S16. 
Contact profiles in the TM-JM segments of W515L TpoR dimers (calculated from the system 
S11CG). Residues from helix 1 are shown along the y-axis and those from helix 2 along the x-axis. 
Color bar indicating the average number of contacts is shown on the right. Contacts were 
calculated with the GROMACS tool gmx mindist: a contact was counted if two residues were 
within a distance of 0.6 nm. The upper left panel indicates the prevailing dimer configuration in 
the simulation. ”II” denotes a parallel configuration for the two TM helices, whereas ”X” 
represents tilted TM helices in the dimer. 
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Table S1. 
Diffusion constants and fractions of immobile particles of TpoR, EpoR and GHR under different 
conditions. 
Receptor JAK2 Ligand D [µm²/s]a D [µm²/s]b D [µm²/s]c D [µm²/s]d Immob.e 
MBP-TMD - - 0.142 ± 
0.008 
- -  0.066 ± 
0.022 
MBP-TMD - mAb 0.081 ± 
0.012 
0.079 ± 
0.018 
-  0.147 ± 
0.067 
TpoR - - 0.141 ± 
0.016 
- 0.128 ± 
0.014 
 0.081 ± 
0.025 
TpoR wt - 0.124 ± 
0.019 
- -  0.062 ± 
0.021 
TpoR - Tpo 0.112 ± 
0.013 
0.102 ± 
0.012 
0.100 ± 
0.013 
 0.104 ± 
0.033 
TpoR wt Tpo 0.097 ± 
0.014 
0.082 ± 
0.010 
-  0.096 ± 
0.062 
TpoR V617F - 0.091 ± 
0.012 
0.079 ± 
0.018 
-  0.114 ± 
0.043 
EpoR - - 0.088 ± 
0.011 
- 0.096 ± 
0.014 
 0.361 ± 
0.088 
EpoR wt - 0.080 ± 
0.016 
- -  0.089 ± 
0.032 
EpoR - Epo 0.085 ± 
0.009 
0.069 ± 
0.006 
0.074 ± 
0.011 
 0.188 ± 
0.044 
EpoR wt Epo 0.073 ± 
0.010 
0.066 ± 
0.013 
-  0.135 ± 
0.037 
EpoR V617F - 0.093 ± 
0.014 
0.072 ± 
0.015 
-  0.102 ± 
0.026 
GHR - - 0.109 ± 
0.016 
- 0.093 ± 
0.016 
 0.131 ± 
0.041 
GHR wt - 0.125 ± 
0.014 
- -  0.107 ± 
0.048 
GHR - GH 0.106 ± 
0.021 
0.087 ± 
0.022 
0.080 ± 
0.014 
 0.127 ± 
0.082 
GHR wt GH 0.097 ± 
0.013 
0.083 ± 
0.017 
-  0.089 ± 
0.031 
GHR V617F - 0.104 ± 
0.015 
0.090 ± 
0.018 
-  0.084 ± 
0.024 
GHR - GH wt - - - 0.077 ± 
0.011 
0.117 ± 
0.037 
GHR - GH G146R - - - 0.102 ± 
0.010 
0.041 ± 
0.012 
a mXFP-tagged receptor, diffusion constant of the total population. 
b mXFP-tagged receptor, diffusion constant of receptor dimers. 
c E3-tagged receptor, diffusion constant of the total population. 
d untagged receptor, diffusion constant of the labeled ligand. 
e fraction of immobile molecules (for mXFP-tagged receptors or labeled GH, respectively).  
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Table S2. 
PICCS evaluation for control proteins, TpoR, EpoR and GHR. 
Condition α [%] a σ [µm] b 
Neg. control 2.6 ± 1.0 0.107 ± 0.048 
Pos. control 23.1 ± 2.4 0.057 ± 0.014 
TpoR unstim. 2.4 ± 1.7 0.118 ± 0.054 
TpoR + TPO 20.8 ± 4.7 0.063 ± 0.008 
EpoR unstim. 2.1 ± 1.6 0.097 ± 0.048 
EpoR + EPO 15.5 ± 6.9 0.069 ± 0.014 
GHR unstim. 2.1 ± 0.8 0.107 ± 0.042 
GHR + GH 16.4 ± 2.3 0.057 ± 0.011 
a The correlated fraction α was related to the localizations of DY647. 
b The correlation length σ describes the apparent average distance between the co-related molecules, which in the 
case of molecular interaction is limited by the co-localization precision. 
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Table S3. 
Two-dimensional equilibrium dissociation constants ܭ஽ଶ஽ for dimerization of different receptors 
and JAK2. 
Receptor JAK2 ligand ࡷࡰ૛ࡰ [µm-2] a ࡷࡰ૛ࡰ [µm-2] b 
TpoR wt - Tpo wt 1.4 ± 0.5  
TpoR wt wt Tpo wt 0.31 ± 0.07  
TpoR wt wt -  112 ± 64 
TpoR-ΔECD wt -  78 ± 50 
TpoR wt V617F - 4.6 ± 2.4 5.1 ± 2.6 
TpoR-ΔECD V617F -  8.4 ±5.2 
TpoR wt V617F Tpo wt 0.005 ± 0.01  
TpoR W515L - - 126 ± 97  
TpoR W515L wt - 33 ± 19  
TpoR W515L V617F - 3.8 ± 2.2  
EpoR wt - Epo wt 3.5 ± 1.1  
EpoR wt wt Epo wt 1.3 ± 0.3  
EpoR wt V617F - 23 ± 16  
EpoR-ΔECD wt -  119 ± 101 
EpoR-ΔECD V617F -  23 ± 10 
GHR wt - GH wt 1.29 ± 0.30  
GHR wt wt GH wt 0.39 ± 0.0  
  -   
GHR wt V617F - 62± 43  
a estimated from single molecule co-tracking analysis 
b estimated from smFRET 
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Table S4. 
Simulated systems (AA – all atom; CG – coarse grained; II – configuration where two TM 
helices are aligned in parallel; X – cross-shaped orientation of the TM dimer). 
System name 
(force field) 
JAK proteins (mutation, 
residues) 
Cytokine receptor  
(mutation, TM/TM pose, 
residues) 
Number of lipid 
molecules (POPC/ 
cholesterol/ 
PIP2/PS) 
Water molecules 
(Na+, Cl-) 
No. 
replicas x 
duration 
(ns) 
S1AA 
(CHARMM36) 
JAK2/JAK2 (WT, 37-1132) 
TpoR/TpoR (WT, 486-578) 
1100/0/0/0 216325 (599, 597) 5 x 1000 
S2AA 
(CHARMM36) 
JAK2/JAK2 (V617F, 37-
1132) 
TpoR/TpoR (WT, 486-578) 
1100/0/0/0 228177 (634, 632) 5 x 1000 
S3AA 
(CHARMM36) 
JAK2/JAK2 (WT, 37-1132) 
TpoR/TpoR (WT, 486-578) 
385/165/0/0 (EC leaflet) 
359/165/27/0 
(IC leaflet) 
235959 (765, 655) 1 x 1000 
S4AA 
(CHARMM36) 
JAK2/JAK2 (WT, 37-1132) 
EpoR/EpoR 
(WT, II-shape, 31-335) 
1100/0/0/0 377794 (1068, 1050) 2 x 1000 
 
S5AA 
(CHARMM36) 
JAK2/JAK2 (WT, 37-1132) 
EpoR/EpoR (WT, X-shape, 
31-335) 
1100/0/0/0 435648 (1230, 1212) 2 x 700 
 
S6AA 
(CHARMM36) 
JAK2 PK/PK (WT, 526-810) N/A 74407 (213,211) 10 x 1000 
S7AA 
(CHARMM36) 
JAK2 PK/PK (V617F, 526-
810) 
N/A 74444 (213,211) 10 x 1000 
 
S8AA 
(CHARMM36) 
TpoR (WT, 486-519) 128/0/0/0 8315 (25, 25) 10 x 1000 
S9AA 
(CHARMM36) 
TpoR (W515L, 486-519) 128/0/0/0 8315 (25, 25) 10 x 1000 
S10CG 
(MARTINI) 
TpoR/TpoR (WT, 486-519) 264/0/0/0 5284 (58, 58) 10 x 20000 
S11CG  
(MARTINI) 
TpoR/TpoR (W515L, 486-
519) 
264/0/0/0 5284 (58, 58) 10 x 20000 
 
S12CG  
(MARTINI) 
TpoR/TpoR (WT, X, 486-
519) 
264/0/0/0 5284 (58, 58) 10 x 20000 
 
S13CG  
(MARTINI) 
TpoR/TpoR (W515L, II, 
486-519) 
264/0/0/0 5284 (58, 58) 10 x 20000 
 
S14CG  
(MARTINI) 
JAK2 (WT, 37-514) 
TpoR(WT, 486-578) 
357/0/0/0 (EC leaflet) 
321/0/0/35 (IC leaflet) 
24229 (306, 276) 10 x 20000 
S15CG  
(MARTINI) 
JAK2 (L224A, 37-514) 
TpoR(WT, 486-578) 
357/0/0/0 (EC leaflet) 
321/0/0/35 (IC leaflet) 
24223 (306, 276) 10 x 20000 
S16CG  
(MARTINI) 
JAK2 (L224E, 37-514) 
TpoR(WT, 486-578) 
357/0/0/0 (EC leaflet) 
321/0/0/35 (IC leaflet) 
24231 (307, 276) 10 x 20000 
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Table S5. 
Persistent residue-by-residue contacts (>60%) at the PK/PK interface of a JAK2 dimer. The data 
were calculated from the simulations of system S6AA using the GROMACS tool gmx mindist with 
a cutoff of 0.6 nm. If two residues were closer to each other than the cutoff distance, they were 
regarded as a contact pair. This procedure was done for every simulation frame, thus the results 
indicate the percentage of frames where a contact was observed for a given residue pair. Only 
interactions with an average contact percentage greater than 60 % are shown. 
JAK2 
monomer 
1 residue 
JAK2 
monomer 
2 residue 
Contact 
percentage 
JAK2 
monomer 
1 residue 
JAK2 
monomer 
2 residue 
Contact 
percentage 
R528 H531 76.63 E596 T530 95.35 
R528 E596 60.40 E596 M532 84.95 
P529 E596 70.99 E596 H531 76.24 
T530 E596 72.38 E596 N533 74.55 
H531 E596 66.83 T668 P529 74.95 
M532 E596 69.50 L669 P529 70.00 
M532 M532 64.65 I670 P529 80.59 
M532 E592 63.27 I670 T530 72.08 
M532 S593 62.08 S703 N533 60.69 
R588 E592 68.12 T705 N533 69.11 
R588 F595 62.38 V706 N533 74.06 
R588 M532 61.19 V706 V536 61.98 
N589 V536 65.05 K728 F537 74.55 
N589 N533 64.75 N729 R528 62.67 
N589 K539 63.17 N729 Q534 61.09 
E592 M532 89.21 L730 R528 71.29 
E592 N533 77.23 L730 Q534 68.12 
E592 E592 68.51 L730 P529 66.24 
E592 V536 60.40 L730 T530 63.86 
S593 M532 74.16 N731 R528 66.83 
S593 N533 66.34 L732 R528 60.30 
F595 E592 61.88    
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Table S6. 
Most prominent changes in residue contact pairs between the WT and V617F JAK2 PK domains. 
Contact percentages were initially calculated using the GROMACS tool gmx mindist using a 
cutoff of 0.6 nm. If two residues were closer to each other than the cutoff distance, they were 
regarded as a contact pair. The procedure was done for every simulation frame, thus the data give 
the percentage of frames in which a contact was observed for a given residue pair. The results 
shown are calculated from systems S6AA and S7AA (see Table S4) by subtracting the V617F 
contact percentage from the WT value. The left side of the table shows contact pairs that are more 
persistent in the WT case, while the right side lists pairs that are more persistent in the mutant 
case. Only values above 25 % are shown. 
Contact pairs amplified in WT Contact pairs amplified in the V617F mutant 
PK 1 
residue 
PK 2 
residue 
Δ(contact 
percent) 
PK 1 
residue 
PK 2 r 
esidue 
Δ(contact  
percent) 
R588 M532 25.54 Q527 Q527 25.25 
R588 V536 26.24 P529 M600 26.93 
R588 K539 29.80 P529 T668 30.10 
N589 N533 25.15 T530 M600 25.35 
N589 K539 33.47 M532 E592 27.92 
E592 N533 25.45 M532 F595 25.35 
F594 N533 28.12 N533 E592 25.74 
E596 Q534 28.91 N533 F594 41.49 
A597 N533 27.72 N533 F595 30.30 
T668 P529 27.62 N533 A597 29.41 
I702 N533 25.64 N533 M600 25.15 
G701 N533 27.72 Q534 I670 33.47 
K728 K603 25.74 Q534 L730 30.30 
L730 Q534 33.37 M535 T705 25.64 
N731 Q534 35.05 F537 V706 25.15 
   V617 R588 30.69 
   V617 N589 28.61 
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Movie S1. 
Raw data from dual-color TIRF imaging of HeLa cells expressing mXFP-TpoR post-
translationally labeled with Rho11NB (top) and DY647NB (bottom). Acquisition frame rate: 30 Hz, 
Playback: real time. 
 
Movie S2. 
Single-step photobleaching of dye-conjugated nanobodies bound to cell surface receptors of 
live cells. Left: unprocessed TIRFM raw data of Rho11NB bound to unstimulated mXFP-TpoR and 
imaged at elevated laser power. Right: superimposition of the fluorescence intensity is shown as a 
3D kymograph (ImageJ volume rendering). Acquisition frame rate: 30 Hz, Playback: real time. 
 
Movie S3. 
Single-molecule co-tracking as a readout for dimerization of cell surface receptors. A 
positive control protein mEGFP-MBP-TMD was labeled with Rho11NB (left, top) and DY647NB 
(left, bottom) and dimerized with monoclonal anti-MBP antibody. In the overlay of the zoomed 
section of both spectral channels (Rho11NB: Red, DY647NB: Blue), yellow lines indicate co-
locomotion trajectories (≥ 10 steps). Acquisition frame rate: 30 Hz, Playback: real time. 
 
Movie S4. 
Dimerization of TpoR co-expressed with wt JAK2 in the absence (left) and presence of 
ligand (center, 5nM TPO, 10 min). Right: ligand-independent dimerization of TpoR co-expressed 
with JAK2 V617F. Identified co-trajectories (≥ 10 steps) are depicted as yellow lines. Red and 
Blue signals correspond to receptors labeled with Rho11NB and DY647NB, respectively. Acquisition 
frame rate: 30 Hz, Playback: real time. 
 
Movie S5. 
Dimerization of EpoR co-expressed with wt JAK2 in the absence (left) and presence of 
ligand (center, 5 nM EPO, 10 min). Right: ligand-independent dimerization of EpoR co-
expressed with JAK2 V617F. Identified co-trajectories (≥ 10 steps) are depicted as yellow lines. 
Red and Blue signals correspond to receptors labeled with Rho11NB and DY647NB, respectively. 
Acquisition frame rate: 30 Hz, Playback: real time. 
 
Movie S6. 
Dimerization of GHR co-expressed with wt JAK2 in the absence (left) and presence of 
ligand (center, 5 nM GH, 10 min). Right: ligand-independent dimerization of GHR co-expressed 
with JAK2 V617F.Identified co-trajectories (≥ 10 steps) are depicted as yellow lines. Red and 
Blue signals correspond to receptors labeled with Rho11NB and DY647NB, respectively. Acquisition 
frame rate: 30 Hz, Playback: real time. 
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Movie S7. 
Single-molecule FRET of mXFP-ΔECD-TpoR dimerized by JAK2 V617F. Unprocessed 
raw TIRFM data of mXFP-ΔECD-TpoR (co-expressed with JAK2 V617F-mEGFP) after labeling 
with Rho11NB and DY647NB, imaged at elevated laser intensities. After 15 frames (~0.5 s) of 
acquisition, the 647 nm laser, used to directly excite DY647NB, was switched off. Acquisition 
frame rate: 30 Hz, Playback: real time. 
 
Movie S8. 
Heterodimerization of EpoR and TpoR by JAK2 V617F. SNAPf-EpoR (labeled with SNAP-
Surface 647: Blue) and mXFP-TpoR (labeled with Rho11NB: Red) were co-expressed with either 
JAK2 wt ΔTK (left) or JAK2 V617F ΔTK (right). Identified co-trajectories (≥ 10 steps) are 
depicted as yellow lines. Acquisition frame rate: 30 Hz, Playback: real time. 
 
Movie S9. 
Dimerization of TpoR W515L in the absence (left) of JAK2 and in cells co-expressing 
JAK2-mEGFP wt (center) or V617F (right). Identified co-trajectories (≥ 10 steps) are depicted as 
yellow lines. Acquisition frame rate: 30 Hz, Playback: real time. 
 
Movie S10. 
Ligand-independent dimerization of TpoR in the presence of JAK2 wt (left) or V617F 
(right) quantified by ALEX smFRET. Trajectories of donor (red) and acceptor (blue) detected 
upon direct excitation are overlaid with FRET trajectories (white). Acquisition frame rate: 50 Hz, 
Playback: real time. 
 
Movie S11. 
Atomistic MD simulation of the transmembrane and intracellular sections of TpoR in 
complex with JAK2 (S1AA). JAK2 monomers 1 (blue) and 2 (red) are shown in surface 
representation with domains highlighted by different shadings: light color: FS; medium color: 
PK; dark color: TK. TpoR monomers 1 (yellow) and 2 (orange) are shown in ribbon 
representation. 
 
Movie S12. 
Atomistic MD simulation of the ligand-induced EpoR dimer in complex with JAK2 (S4AA). 
JAK2 monomers 1 (blue) and 2 (red) are shown in surface representation with domains 
highlighted by different shadings: dark color: FS; light color: PK; medium color: TK. EpoR 
monomers 1 (yellow) and 2 (green) and Epo (purple) are shown in ribbon representation. 
 
Movie S13. 
Dimerization of TpoR TM helices and amphipathic motifs (486-519) in CG description 
(S12CG).  
 
